Latest / Ageless and Timeless Podcast® / Longevity: Hope, Hype, and Science with Dr . Bill Lawrence

Transcript

Longevity: Hope, Hype, and Science with Dr . Bill Lawrence · Ageless and Timeless Podcast®

• 0:12
  Speaker 1: Good morning everyone.
• 0:13
  Speaker 2: This is Michelle Hughes from Ageless and Timeless. Today is
• 0:17
  Speaker 2: a very special day. I have a guest who's been
• 0:20
  Speaker 2: a good friend of mine for three years and met
• 0:22
  Speaker 2: him through the longevity world and through a mutual friend
• 0:27
  Speaker 2: and he was on my podcast in twenty twenty three.
• 0:31
  Speaker 2: And his name is doctor Bill Lorentz. I say Lawrence,
• 0:35
  Speaker 2: but a lot of people say Lorentz. So which do
• 0:38
  Speaker 2: you prefer?
• 0:38
  Speaker 1: Bill?
• 0:39
  Speaker 3: Either one is just fine, Okay, Well.
• 0:41
  Speaker 2: One is more French Canadian and the other one is
• 0:44
  Speaker 2: more basic American.
• 0:46
  Speaker 1: So anyway, Bill, welcome back.
• 0:49
  Speaker 2: It's been an incredible three years that I want to
• 0:53
  Speaker 2: fill in the blanks on and I see you increased
• 0:56
  Speaker 2: your hair volume since.
• 0:58
  Speaker 4: We last, Doc, well, I just haven't had a chance
• 1:02
  Speaker 4: to get a haircut.
• 1:03
  Speaker 1: To get to get a haircut.
• 1:04
  Speaker 2: Okay, Well, you're looking great and very trim and muscular
• 1:08
  Speaker 2: and all good. So let me just give people a
• 1:11
  Speaker 2: little bit of the backstory that some people that are
• 1:15
  Speaker 2: with us today might not.
• 1:16
  Speaker 1: Have been with us three years ago.
• 1:18
  Speaker 2: And by the way, everybody, this is my eighth year
• 1:21
  Speaker 2: just celebrated of hosting Ageless and Timeless. So it's been
• 1:26
  Speaker 2: an incredible journey and Bill Warrens is just one of
• 1:30
  Speaker 2: many that, but he's one of the very special ones.
• 1:33
  Speaker 1: So just all transparency.
• 1:35
  Speaker 2: He has been under the guidance of a doctor Cavinson
• 1:41
  Speaker 2: who has unfortunately passed away last year I guess it was,
• 1:45
  Speaker 2: and he was Bill's mentor, and he was the head
• 1:49
  Speaker 2: of the gerontology lab at Saint Petersburg, and he's the
• 1:54
  Speaker 2: one that putin assigned the role to find a way
• 1:58
  Speaker 2: to help the well their astronauts and their victims of
• 2:06
  Speaker 2: the Chernobyl and even Olympic athletes to increase their longevity
• 2:13
  Speaker 2: and get over some of their hurdles that they had suffered.
• 2:16
  Speaker 2: So it's the peptide bioregulators as the industry that emerged
• 2:21
  Speaker 2: as a result. And for forty years in the Soviet
• 2:25
  Speaker 2: Union in Russia they've been buying these peptides right in
• 2:29
  Speaker 2: a pharmacy. But for the US it's all very new
• 2:32
  Speaker 2: and we can thank doctor Bill for bringing the peptide
• 2:36
  Speaker 2: bioregulators to the United States. So once again, Bill, I
• 2:39
  Speaker 2: want to thank you because I've been one of your
• 2:42
  Speaker 2: quote victims in your program and I can only say
• 2:46
  Speaker 2: that well, I did my biological versus chronological tests with
• 2:53
  Speaker 2: true diagnostics only I think a year ago, and I
• 2:56
  Speaker 2: was about fifteen years younger. So we'll see what happens
• 3:01
  Speaker 2: when we do it again next year. But I feel
• 3:05
  Speaker 2: very proud that I've been and very thankful and grateful
• 3:10
  Speaker 2: that I've been under your guidance all these three years
• 3:13
  Speaker 2: taking the peptid bioregulators and seeing those improvements. So doctor
• 3:19
  Speaker 2: Bill is an interesting backstory. He was an attorney, a
• 3:23
  Speaker 2: real estate developer like I am, and he when he
• 3:28
  Speaker 2: realized that his whole family had died very young and
• 3:32
  Speaker 2: he was reaching the age where most of them had
• 3:34
  Speaker 2: reached their mortality, he decided that that was not going
• 3:37
  Speaker 2: to be his fate, and he went and got his
• 3:41
  Speaker 2: PhD in nutritional science, and then he very very uniquely,
• 3:46
  Speaker 2: because not very many people would ever have the guts
• 3:49
  Speaker 2: to do this. But he found out about doctor Cavinson,
• 3:51
  Speaker 2: and he actually flew to Russia and he knocked on
• 3:55
  Speaker 2: their door and they took him in and he became
• 3:59
  Speaker 2: their disciple, their protege, and that's how we in the
• 4:02
  Speaker 2: United States have gotten these peptides bioregulators, which are the
• 4:07
  Speaker 2: oral version of the peptides you're hearing so much about
• 4:11
  Speaker 2: online right now, but I can tell you that these
• 4:13
  Speaker 2: are the authentic peptides that are not being developed in
• 4:18
  Speaker 2: China and sold on Instagram like so many of them
• 4:21
  Speaker 2: these days.
• 4:22
  Speaker 1: So doctor Bill, welcome back. And I just want to
• 4:25
  Speaker 1: ask you.
• 4:25
  Speaker 2: A quick intro question because I'm sure people who did
• 4:29
  Speaker 2: see you three years ago want to know what has
• 4:32
  Speaker 2: changed in your purview of the peptide bioregulator world in
• 4:38
  Speaker 2: the three years since we've been together.
• 4:43
  Speaker 3: Okay, it's a good question.
• 4:44
  Speaker 4: Very little actually has changed in the actual peptide bioregulator
• 4:49
  Speaker 4: world itself. I mean, we're still using the peptides that
• 4:52
  Speaker 4: Professor Cavinson developed over forty some odd years. We've expanded
• 4:58
  Speaker 4: the clinical study.
• 5:00
  Speaker 3: Quick history.
• 5:01
  Speaker 4: We started the Telemere clinical study roughly about twenty ten
• 5:06
  Speaker 4: or so, I think that was right, No, two thousand fifteen.
• 5:11
  Speaker 4: Excuse me, now, I went to Russia in twenty ten.
• 5:15
  Speaker 4: So we started Telemere tests because telomeres are a good
• 5:18
  Speaker 4: proxy for longevity, and my focus is really the longevity.
• 5:22
  Speaker 3: Aspect of bioregulators.
• 5:25
  Speaker 4: They're also used for organ regeneration, and in the slide
• 5:28
  Speaker 4: show that I'm going to present, I touch on that
• 5:30
  Speaker 4: a little bit, but my focus truly is longevity. How
• 5:33
  Speaker 4: can we reverse the biological age of humans, slow it
• 5:37
  Speaker 4: down and then reverse it and we can we have
• 5:40
  Speaker 4: the proof. The other thing that's changed is that the
• 5:43
  Speaker 4: about two thousand and twenty twenty, I guess we were
• 5:50
  Speaker 4: able to start doing what we call epigenetic testing, which
• 5:52
  Speaker 4: I'll explain a little bit later, into the pepti or
• 5:56
  Speaker 4: into the powerpoints. So that gave us another proc to
• 6:01
  Speaker 4: be able to determine biological age. So we can measure
• 6:05
  Speaker 4: people's biological age with these two proxies, one the telomeres
• 6:08
  Speaker 4: and then the epigenetics.
• 6:10
  Speaker 3: What has changed is with in.
• 6:13
  Speaker 4: A sense, all technology transforms gets better and better, more specific.
• 6:19
  Speaker 4: And so when we started off with the epigenetics, we
• 6:24
  Speaker 4: could just get a biological age for you call it
• 6:28
  Speaker 4: the gene system. Then it was we could split it
• 6:31
  Speaker 4: up and get an overall biological age, and we could
• 6:34
  Speaker 4: get a separate biological age of the immune system. And
• 6:38
  Speaker 4: then it transformed after that too. We now can get
• 6:41
  Speaker 4: the biological age. And I don't by the way, I
• 6:44
  Speaker 4: don't like that term biological age, but it's the buzzword
• 6:46
  Speaker 4: that everybody sort of understands it's much more complex. Anyway,
• 6:50
  Speaker 4: we can now get the biological age of nineteen organs
• 6:53
  Speaker 4: and systems of a human being. In other words, we
• 6:56
  Speaker 4: can determine, you know, with a variance of a year
• 6:59
  Speaker 4: or two, we can determine the age of your heart, Michelle,
• 7:06
  Speaker 4: the age of your brain, you're pancreas, your liver, your kidney,
• 7:10
  Speaker 4: and so forth. And when we get that information, I
• 7:13
  Speaker 4: then prepare a protocol. My sister and I do a
• 7:19
  Speaker 4: protocol exactly here. Come here, since you've talked to Laurie.
• 7:25
  Speaker 2: Yeah, Laurie, nice to finally meet you.
• 7:31
  Speaker 1: You've been extremely competent and helpful. Thank you.
• 7:35
  Speaker 3: Yes, she certainly is.
• 7:36
  Speaker 4: So we create a protocol, and we now have twenty
• 7:41
  Speaker 4: one of these different peptide bioregulators. And so when I
• 7:44
  Speaker 4: get the epigenetic breakdown of these nineteen systems, and I
• 7:49
  Speaker 4: see that the heart is accelerated in terms of its
• 7:52
  Speaker 4: biological aging, or the liver or the kidney, then I
• 7:55
  Speaker 4: can build Actually, Laurie and I then build that protocol
• 7:58
  Speaker 4: to address that issue. Have kind of a standard protocol
• 8:02
  Speaker 4: for longevity itself, and then we add the additional ones
• 8:06
  Speaker 4: for anything that is biologically age and quicker.
• 8:09
  Speaker 3: So that's a big change that we can be that specific.
• 8:13
  Speaker 2: I agree, I totally agree, and I can't wait to
• 8:15
  Speaker 2: be tested in that way because my tests are older
• 8:19
  Speaker 2: and they were just a more generic one. Well, I
• 8:22
  Speaker 2: don't want to take away from what is really important
• 8:25
  Speaker 2: today in this presentation, which is that kind of what
• 8:29
  Speaker 2: you did last time three years ago, but much upgraded,
• 8:33
  Speaker 2: as you said in.
• 8:34
  Speaker 1: Your email to me.
• 8:36
  Speaker 2: So why don't you go ahead and take over and
• 8:39
  Speaker 2: you be the teacher today and let all of us
• 8:42
  Speaker 2: be your students.
• 8:44
  Speaker 4: Be happy to do so, let's bring up the slide
• 8:48
  Speaker 4: show at this point. What I'm interested in, particularly these
• 8:53
  Speaker 4: days as a longevity scientist, what I'm really interested in
• 8:58
  Speaker 4: is we see this word longevity tossed around the internet
• 9:04
  Speaker 4: on youtubes and so forth. And in fact, when I
• 9:08
  Speaker 4: did a check with the youtubes, there were over five
• 9:11
  Speaker 4: hundred thousand youtubes with the title longevity.
• 9:15
  Speaker 3: And then.
• 9:17
  Speaker 4: And so about six months ago, because I've been in
• 9:20
  Speaker 4: this field for thirty years and then about eleven years
• 9:24
  Speaker 4: with the Russians, I realized that there's a huge amount
• 9:28
  Speaker 4: of confusion in terms of longevity and what I break
• 9:34
  Speaker 4: it down into and this presentation is going to talk
• 9:36
  Speaker 4: about things that are longevity hopeful, Okay, things that are
• 9:41
  Speaker 4: pertaining to longevity that are just out and out hype.
• 9:45
  Speaker 3: And then the real science. And the real.
• 9:48
  Speaker 4: Science in terms of longevity interventions is quite small. It's
• 9:52
  Speaker 4: only really about eight or nine interventions as I call them,
• 9:56
  Speaker 4: have any scientific basis. They have you know, public clinical
• 10:00
  Speaker 4: studies and lab work and so forth. So what I'm
• 10:04
  Speaker 4: doing with this presentation is I'm separating out what's hopeful,
• 10:11
  Speaker 4: what's hype, and what's actually science in longevity.
• 10:16
  Speaker 1: Well, I can tell you that that's very, very compelling
• 10:19
  Speaker 1: and very.
• 10:20
  Speaker 2: Much needed because there's an awful lot of charlatans up
• 10:23
  Speaker 2: there that you know, people don't know that they how
• 10:27
  Speaker 2: they have to separate the hype from the hope from
• 10:31
  Speaker 2: the science.
• 10:32
  Speaker 1: Right, So let's dive in. I'm ready.
• 10:37
  Speaker 2: Cellular protection is a key component of longevity, and that's
• 10:41
  Speaker 2: where C sixty enters the conversation. Known for its powerful
• 10:46
  Speaker 2: antioxidant properties, C sixty is being explored for its role
• 10:51
  Speaker 2: in reducing oxidative stress and supporting cellular resilience. As interest
• 10:56
  Speaker 2: grows around mitochondrial health and aging at the cellular level,
• 11:01
  Speaker 2: C sixty continues to stand out as a fascinating area
• 11:04
  Speaker 2: of research and application. It's exactly the kind of forward
• 11:09
  Speaker 2: looking wellness solution we aim to spotlight on. Ageless and Timeless.
• 11:14
  Speaker 2: For more information on C sixty and how it's being
• 11:18
  Speaker 2: used in longevity focused routines, check the affiliate link in
• 11:22
  Speaker 2: the show notes, or use Ageless ten for ten percent
• 11:26
  Speaker 2: off your.
• 11:27
  Speaker 1: Purchase of all their products.
• 11:30
  Speaker 2: All right, well, okay, so I think one of the
• 11:34
  Speaker 2: biggest questions today, Bill that I get all the time,
• 11:37
  Speaker 2: and I know you can help with this, is what
• 11:40
  Speaker 2: is the difference? And I know you're going to what
• 11:42
  Speaker 2: you're going to say.
• 11:43
  Speaker 1: But let me just ask it anyway. It's rhetorical.
• 11:46
  Speaker 2: What is the difference between peptide bioregulators and injectable peptides
• 11:51
  Speaker 2: that are all over.
• 11:52
  Speaker 1: The world right now?
• 11:53
  Speaker 2: Is one of the hottest new developments in the longevity space.
• 11:59
  Speaker 4: Great question, and there is a big difference. What I
• 12:04
  Speaker 4: call the synthetic or the therapeutic peptides are wonderful. In fact,
• 12:09
  Speaker 4: I'm using several myself, and my belief is that you
• 12:13
  Speaker 4: should use those as well as the bioregulators because they
• 12:16
  Speaker 4: target different things. The synthetic peptides target acute situations BPC.
• 12:23
  Speaker 4: Let's say one fifty seven for instance, if you've got
• 12:26
  Speaker 4: tendon problems, ligament problems, wounds, and so forth, that's where
• 12:30
  Speaker 4: you want to be because it is effective and it's
• 12:33
  Speaker 4: effective in the short term. On the other hand, the
• 12:36
  Speaker 4: bioregulators are things that take quite a bit of time
• 12:40
  Speaker 4: because they're regentitive. In never words, if we are using them,
• 12:43
  Speaker 4: say for liver support, it's going to take eighteen months
• 12:47
  Speaker 4: to two years to fully address all of the issues
• 12:51
  Speaker 4: of say a sixty or seventy year old person in
• 12:54
  Speaker 4: terms of their liver. So they're very slow, and it's
• 12:57
  Speaker 4: the bioregulators that will change person's biological age. The synthetic
• 13:02
  Speaker 4: peptides will not do that, but they are very useful
• 13:06
  Speaker 4: for targeting acute problems. That's why I say you should
• 13:09
  Speaker 4: be using both the acute ones, the synthetics, as well
• 13:13
  Speaker 4: as the bio regulators in a program. The first thing
• 13:17
  Speaker 4: is obvious to everybody, and that is the value of time.
• 13:21
  Speaker 4: And Steve Jobs, you know, has made a statement, by
• 13:25
  Speaker 4: the way, are people not Are there people who are
• 13:28
  Speaker 4: going to only be able to listen or is everyone
• 13:30
  Speaker 4: going to see this everything?
• 13:32
  Speaker 2: Well, a couple of the podcasts are still audio only,
• 13:37
  Speaker 2: but we're on every podcast major podcast site, and plus
• 13:42
  Speaker 2: we have our own YouTube channel, and so I would
• 13:48
  Speaker 2: say eighty percent will be visual.
• 13:51
  Speaker 3: Okay. I don't have to spend a lot of time
• 13:53
  Speaker 3: reading things that people you know.
• 13:55
  Speaker 2: And people who go on one audio can always switch
• 13:59
  Speaker 2: to another one knowing that this is going to be
• 14:01
  Speaker 2: a visual, So I would worry about that.
• 14:04
  Speaker 4: I just do your thing, great, Okay, So the issue
• 14:08
  Speaker 4: here is the value of time. Steve Jobson said in
• 14:11
  Speaker 4: a statement that it's really clear that the most precious
• 14:14
  Speaker 4: resource we all have is time, and that's absolutely true.
• 14:18
  Speaker 4: Much more valuable than money or fame or anything else
• 14:21
  Speaker 4: is how much healthy time do we have in this world?
• 14:25
  Speaker 4: And then Thomas Edison many many years ago said that
• 14:29
  Speaker 4: time is really the only capital that any human being
• 14:32
  Speaker 4: has and the only thing he can't afford to lose.
• 14:35
  Speaker 4: What's interesting is that we're seeing billionaires now realizing of
• 14:39
  Speaker 4: course this, and they're funding foundations and scientific investigations basically
• 14:48
  Speaker 4: to be able to extend their time. Okay, now going
• 14:53
  Speaker 4: to get I'm going to go quick through some of
• 14:54
  Speaker 4: these because it's all it's the data that counts.
• 14:57
  Speaker 3: I'm an attorney, I'm a scientist. I've been in this.
• 15:00
  Speaker 4: Field thirty years at this point. What this slide is, basically,
• 15:04
  Speaker 4: the message is you have to have the evidence. If
• 15:08
  Speaker 4: I'm going to look at something, you better bring the evidence.
• 15:11
  Speaker 4: And by evidence, I mean published clinical studies, lots of
• 15:16
  Speaker 4: lab results showing before and after. And as we're going
• 15:19
  Speaker 4: to talk about in this field of longevity, it's very
• 15:23
  Speaker 4: light on evidence. That is, there's a lot of claims
• 15:25
  Speaker 4: that are made. But in my world, you better bring
• 15:29
  Speaker 4: the evidence. And I'm a gero scientist, you can say.
• 15:35
  Speaker 4: And what that's all about is that we believe that
• 15:38
  Speaker 4: the root cause of a lot of things like cancer, dementia,
• 15:42
  Speaker 4: cardiovasco disease, and chronic illness really.
• 15:46
  Speaker 3: Starts with the aging process. That is, if we can.
• 15:50
  Speaker 4: Improve the age of the biological aging process, many of
• 15:54
  Speaker 4: these things will be mutated to some degree, reduced, maybe
• 15:58
  Speaker 4: even eliminated. But you've got to start with what we
• 16:02
  Speaker 4: call the root cause, which is just human aging. And
• 16:05
  Speaker 4: we know of course that as people age biologically chronologically,
• 16:08
  Speaker 4: but they become subject to all of these types of diseases.
• 16:12
  Speaker 4: So our focus is, let's focus on aging what's very
• 16:18
  Speaker 4: confusing out there is that we have these terms lifespan,
• 16:22
  Speaker 4: health span, and biological longevity, and they are oftentimes overlapped
• 16:28
  Speaker 4: and they're confusing to people what lifespan is. And it's
• 16:31
  Speaker 4: important that we understand going into this presentation the difference
• 16:35
  Speaker 4: between these because what lifespan is the total years that
• 16:39
  Speaker 4: a person has lived, and we can increase the number
• 16:44
  Speaker 4: of years by enhancing their health span. But lifespan is
• 16:48
  Speaker 4: just how many years are you going to basically live.
• 16:51
  Speaker 4: Health Span, then is different. Health span is how many
• 16:55
  Speaker 4: years can you live in good health? And I'm going
• 16:57
  Speaker 4: to show some stats in a moment about the difference
• 17:00
  Speaker 4: between lifespan and health span.
• 17:02
  Speaker 3: The focus there is on function, vitality, independence, delaying disease.
• 17:07
  Speaker 4: That's health span. Okay, then the third category what I'm
• 17:11
  Speaker 4: showing here is biological longevity interventions, which is basically what
• 17:15
  Speaker 4: I'm doing. And what we're doing is we're targeting the
• 17:19
  Speaker 4: mechanisms of aging like telomeres and epigenetics and so forth,
• 17:23
  Speaker 4: in order to improve both the lifespan the health span
• 17:28
  Speaker 4: and be able to create fifteen or twenty years of
• 17:32
  Speaker 4: additional longevity but in a healthy state. So we have
• 17:35
  Speaker 4: to differentiate between lifespan, health span, and longevity.
• 17:41
  Speaker 2: Okay, well that's very helpful, Bill, because everybody talks about
• 17:44
  Speaker 2: lifespan and health span, but very few people ever mentioned
• 17:47
  Speaker 2: the third biological longevity interventions, which is really, you know,
• 17:52
  Speaker 2: the probably the most is the most important aspect of this.
• 17:57
  Speaker 4: So thank you, You're welcome. They're all important, particularly health span,
• 18:02
  Speaker 4: and we're going to see some remarkable statistics that are
• 18:05
  Speaker 4: rather disturbing for Americans. In fact, this slide shows that
• 18:09
  Speaker 4: the Americans have shorter lives than most of the rest
• 18:12
  Speaker 4: of the world. This is a chart showing the average
• 18:16
  Speaker 4: longevity in terms of chronological age of Americans, and the
• 18:21
  Speaker 4: blue is for men, the red is for women. Notice
• 18:25
  Speaker 4: the huge difference between the men women of America and
• 18:30
  Speaker 4: those in Japan, Switzerland, Australia, Canada, and the United Kingdom.
• 18:34
  Speaker 4: They are five to seven years. They have five to
• 18:36
  Speaker 4: seven more longevity years than the typical American. That is
• 18:41
  Speaker 4: a real statement about where we are as a nation
• 18:45
  Speaker 4: in terms of our health.
• 18:48
  Speaker 2: And we spend more money than any other country on healthcare.
• 18:52
  Speaker 4: Yeah, by several times we per capita, we spend more
• 18:56
  Speaker 4: money than the rest of all the other countries collectively
• 19:00
  Speaker 4: just a real broken system.
• 19:02
  Speaker 3: I'm preaching to the choir with you. You understand that.
• 19:06
  Speaker 4: So anyway, Americans live shorter. Okay, ye, now here's here's
• 19:12
  Speaker 4: health span. Okay, not lifespan. Here's health span in other words,
• 19:17
  Speaker 4: how long are are Americans and others and other countries.
• 19:21
  Speaker 3: How long are they healthy for?
• 19:22
  Speaker 4: How many years are they basically functional versus the years
• 19:27
  Speaker 4: that they're dealing with disease, chronic disease, et cetera. And
• 19:31
  Speaker 4: notice the United States and this has about sixty four
• 19:35
  Speaker 4: years on average both sexes, sixty four years of functional
• 19:39
  Speaker 4: health and from sixty four years onward. In America it's
• 19:43
  Speaker 4: kind of downhill for most people. And if you compare
• 19:47
  Speaker 4: to the other countries, they are typically five, six, seven,
• 19:51
  Speaker 4: eight years longer in health span, in other words, how
• 19:54
  Speaker 4: long they're healthy and what their situation is like. If
• 19:58
  Speaker 4: we look at Japan, health span is seventy seventy three years, well,
• 20:04
  Speaker 4: their lifespan is about ten more years than that, so
• 20:06
  Speaker 4: they have about eight or ten years of problematic, challenging
• 20:10
  Speaker 4: health issues. On the other hand, in America, at sixty
• 20:14
  Speaker 4: four years of health span, we're looking at fifteen to twenty.
• 20:18
  Speaker 3: Years of dealing with disease.
• 20:20
  Speaker 1: Wow.
• 20:23
  Speaker 4: So what this chart shows is lifespan versus health span
• 20:26
  Speaker 4: in the United States, and so the life expectancy of
• 20:31
  Speaker 4: males in America is seventy six point five years and
• 20:35
  Speaker 4: for women it's eighty one point four years. The healthy
• 20:39
  Speaker 4: life expectancy though for men is actually sixty four years
• 20:44
  Speaker 4: or twelve years less than their life expectancy, and for
• 20:49
  Speaker 4: women it's sixty six years or fifteen to sixteen years
• 20:53
  Speaker 4: in a chronic disease disability kind of situation. That's a
• 20:58
  Speaker 4: long time for people to be battling with disease at
• 21:01
  Speaker 4: this point. And so when we talk about some of
• 21:05
  Speaker 4: these interventions, keep in mind that health span is targeting
• 21:09
  Speaker 4: keeping people healthy longer. On the other hand, longevity is
• 21:14
  Speaker 4: adding additional years to their normal number of years that
• 21:17
  Speaker 4: they would have. But what's disturbing about this is again
• 21:21
  Speaker 4: for men, they're twelve to thirteen years of their life
• 21:24
  Speaker 4: going to be lived with disease and disability, for the
• 21:28
  Speaker 4: women fifteen to sixteen years.
• 21:32
  Speaker 1: Amazing.
• 21:35
  Speaker 4: Okay, So I have a different criteria as I say,
• 21:39
  Speaker 4: I've been in this field for decades and I spent
• 21:41
  Speaker 4: ten years with the Russians and so forth. My definition
• 21:46
  Speaker 4: of longevity is ext a significant extension beyond normal life span. Okay,
• 21:55
  Speaker 4: And so the criteria that we use in our clinical studies,
• 21:59
  Speaker 4: we have to be able to change a person's biological age,
• 22:04
  Speaker 4: let's say by at least three out of these five.
• 22:08
  Speaker 3: Sometimes that we look at four.
• 22:10
  Speaker 4: These are the things that we can do that we've
• 22:13
  Speaker 4: proved we can do that, the Russians proved it, and
• 22:15
  Speaker 4: so forth. So our criteria is we've got to reduce
• 22:19
  Speaker 4: people's telemeter age as we call it, and we're getting
• 22:23
  Speaker 4: get in more detail by twenty years. Okay, we have
• 22:26
  Speaker 4: to change the epigenetic age. This would be generation lab
• 22:31
  Speaker 4: than true diagnostic. We have to change that ep epigenetic clock.
• 22:36
  Speaker 4: We have to slow it down by at least seven years,
• 22:39
  Speaker 4: and we're going to show what we do to do that.
• 22:41
  Speaker 4: The epigenetic all cause mortality risk has to be reduced
• 22:45
  Speaker 4: by fifty percent in order for it to fit my criteria.
• 22:50
  Speaker 4: We also have this concept of pace of aging that
• 22:52
  Speaker 4: I'm going to spend a little more time talking about.
• 22:55
  Speaker 4: We have to reduce people's pace of aging. And what
• 22:59
  Speaker 4: we have is understands chronological aging, but we're now looking
• 23:03
  Speaker 4: and we can determine what a person's biological rate of
• 23:06
  Speaker 4: aging is. And in our clinical study, our goal is
• 23:10
  Speaker 4: to slow it by ten percent. And then we're going
• 23:13
  Speaker 4: to talk about the Hayflick limit for a few minutes
• 23:16
  Speaker 4: at some point. But our criteria is we've got to
• 23:21
  Speaker 4: extend the hate flick limit by at least thirty percent.
• 23:24
  Speaker 4: That's my criteria for longevity. Anything less than that tends
• 23:30
  Speaker 4: to be a mortality reduction or health span.
• 23:34
  Speaker 2: So I think you're going to I know that you're
• 23:36
  Speaker 2: going to explain these because most people don't know what
• 23:38
  Speaker 2: the duned in and the hayflick and the whovat the
• 23:41
  Speaker 2: other two. Yes, I mean most people know what to
• 23:43
  Speaker 2: tellomir is and epigenetics, of course, is the lifestyle version
• 23:49
  Speaker 2: of your genetics.
• 23:50
  Speaker 1: Right, So I'll let you keep going.
• 23:52
  Speaker 2: But those are three that I'm sure people are asking
• 23:55
  Speaker 2: themselves what are they?
• 23:57
  Speaker 4: And I'm going to talk about each one of those. Okay,
• 24:01
  Speaker 4: So what this slide is talking about is longevity hope.
• 24:05
  Speaker 4: That is, we don't have any human longevity evidence, but
• 24:09
  Speaker 4: with animal studies and lab work and so forth, we
• 24:12
  Speaker 4: believe that this is on the horizon and I know
• 24:16
  Speaker 4: that the first one here, stem cells, is a lot
• 24:18
  Speaker 4: of your expertise, so you know much more about where
• 24:23
  Speaker 4: we are in terms of longevity and stem cells.
• 24:27
  Speaker 3: I place it into the hope category because.
• 24:30
  Speaker 4: I don't think we have a huge amount of published
• 24:33
  Speaker 4: clinical studies for longevity. We have a lot of studies
• 24:36
  Speaker 4: using stem cells to treat health span for health issues.
• 24:40
  Speaker 3: Is that a fair assessment?
• 24:42
  Speaker 1: Very much so? And you know a lot of it
• 24:44
  Speaker 1: is experiential.
• 24:46
  Speaker 2: Is experiential, I mean it's the people, the feedback from
• 24:49
  Speaker 2: the people who feel better like and that's really like
• 24:53
  Speaker 2: the cutting edge is how do you feel?
• 24:56
  Speaker 1: The big question? How do you feel? What's the difference?
• 25:00
  Speaker 2: So a lot of this is not done through science,
• 25:02
  Speaker 2: which is often very expensive to do those studies, but
• 25:06
  Speaker 2: it's done more by interviewing the users.
• 25:11
  Speaker 3: Yes, that's why I call it longevity hope.
• 25:14
  Speaker 4: I hope that all of these and what we're talking
• 25:16
  Speaker 4: about is NAD therapy, hyperbaric met formans, and analytics reprimison.
• 25:21
  Speaker 4: These are all things that we hope can be turned
• 25:24
  Speaker 4: into human evidence. And we're going to talk a little
• 25:27
  Speaker 4: bit in a moment about the difference between animal evidence
• 25:30
  Speaker 4: versus human evidence.
• 25:31
  Speaker 1: Right.
• 25:33
  Speaker 4: Okay, Now, at this point we're in this grouping, we're
• 25:37
  Speaker 4: basically looking at experimental longevity interventions, things that are stilled.
• 25:42
  Speaker 4: Just as you mentioned, Michelle, we don't have multiple clinical studies,
• 25:47
  Speaker 4: but we have feedback from people, we have lab reports,
• 25:51
  Speaker 4: and the six that I've listed here are experimental, and
• 25:54
  Speaker 4: I hope every one of them can be created. So
• 25:58
  Speaker 4: what we call, and I'm going to explain what each
• 26:00
  Speaker 4: one of these is sell your reprogramming. Okay, gene therapy, synalytics,
• 26:06
  Speaker 4: stem cells there, immune rejuvenation, and plasma exchange. Those are
• 26:10
  Speaker 4: the things that I consider to be experimental, just because
• 26:13
  Speaker 4: we don't have enough published clinical study with humans to
• 26:17
  Speaker 4: say that yes, that one is effective for certain. They're
• 26:20
  Speaker 4: in the infancy at this point. So sell your reprogramming
• 26:26
  Speaker 4: very very complicated. What scientists do is they introduce a
• 26:31
  Speaker 4: special set of proteins into our cells. And what they're
• 26:35
  Speaker 4: doing is you could think of it as you've got
• 26:38
  Speaker 4: your computer hard drive and you bring in a new
• 26:42
  Speaker 4: set of data that you want to load to it
• 26:45
  Speaker 4: because it'll make it function much better. That's sort of
• 26:48
  Speaker 4: the idea of sell your reprogram You're changing the biological
• 26:51
  Speaker 4: makeup of cells. It's experimental at this point, but we
• 26:57
  Speaker 4: have some basic, sort of preliminary that this.
• 27:00
  Speaker 3: Could be workable.
• 27:02
  Speaker 4: We could be able to control by changing the cell
• 27:05
  Speaker 4: your makeup of our cells with certain proteins.
• 27:09
  Speaker 3: So it's very very hopeful.
• 27:11
  Speaker 4: The idea is to take old identify older cells, which
• 27:14
  Speaker 4: is possible to do, and turn them into younger cells.
• 27:18
  Speaker 4: That again, it's in the experimental category gene editing, okay,
• 27:24
  Speaker 4: what we call crisper and so forth. What we're doing
• 27:27
  Speaker 4: here is the science world is basically identifying where there
• 27:34
  Speaker 4: are mutations or weaknesses or broken in our DNA what
• 27:41
  Speaker 4: we call mutations, and we're able to kind of identify
• 27:45
  Speaker 4: at that level where there's an issue, where there's something
• 27:48
  Speaker 4: that when the cell was replicating, it didn't replicate perfectly
• 27:51
  Speaker 4: and so there's a gap, there's a break, and so forth.
• 27:54
  Speaker 4: And the idea with gene editing is that we can
• 27:56
  Speaker 4: go in like with a pair of scissors and cut
• 27:59
  Speaker 4: in to that gene area along with the chromosomes, and
• 28:04
  Speaker 4: we can pull out a defective piece of it and
• 28:07
  Speaker 4: then reattach. It very very experimental at this point, but
• 28:12
  Speaker 4: it has, you know, possibilities, and then we get to
• 28:18
  Speaker 4: longevity hype, okay, and there's a lot of it out there.
• 28:22
  Speaker 4: I can't tell you, and I'm sure you, Michelle run
• 28:25
  Speaker 4: in this all the time as well. Where you click
• 28:28
  Speaker 4: on YouTube and there's a longevity claim made, you know,
• 28:32
  Speaker 4: backed by science, or the five Supplements for longevity, stem
• 28:37
  Speaker 4: cell renew supplement, all those kinds of claims are made,
• 28:41
  Speaker 4: and that's the hype. And unfortunately, I think that about
• 28:44
  Speaker 4: ninety percent or more of what's on Fortunately, unfortunately on
• 28:49
  Speaker 4: YouTube and some of these other sites, a lot of
• 28:51
  Speaker 4: it's hype because there's really no evidence for most of it.
• 28:55
  Speaker 4: It's either in the hope category or it's just out
• 28:58
  Speaker 4: and out hype. And identify height by things like when
• 29:02
  Speaker 4: it has elite endorsements. I think you call them, is
• 29:05
  Speaker 4: it influencers?
• 29:07
  Speaker 3: Is that what they call it?
• 29:08
  Speaker 1: That's what they're called on particularly on Instagram.
• 29:11
  Speaker 4: Yeah, okay, So you have an influencer who has a say,
• 29:16
  Speaker 4: a large following on their social media and so forth,
• 29:20
  Speaker 4: and so.
• 29:20
  Speaker 3: They come out and they.
• 29:22
  Speaker 4: Endorse a particular thing, you know, some capsules or supplements
• 29:26
  Speaker 4: or whatever it may be. And of course they're getting
• 29:28
  Speaker 4: a paid a percentage for any sales. What they end
• 29:31
  Speaker 4: up saying is if you purchase and use my name
• 29:35
  Speaker 4: and so forth, you'll get a fifteen percent discount. And
• 29:38
  Speaker 4: so people will tend to believe that that's probably you know,
• 29:43
  Speaker 4: if you've got an important individual, you know, with credentials,
• 29:47
  Speaker 4: doctors and all the rest of that stuff. Scientists, it's
• 29:50
  Speaker 4: probably a valid thing and there's probably some science behind it. Unfortunately,
• 29:53
  Speaker 4: it's the rare situation when there's some real science behind it,
• 29:57
  Speaker 4: so you have to be aware of it. Like if
• 29:59
  Speaker 4: there's a offers you know, we only have one hundred
• 30:02
  Speaker 4: bottles left, or claims that they're you know, the government
• 30:05
  Speaker 4: is suppressing and so forth. Those are all I think
• 30:08
  Speaker 4: signs that there's probably you're in the probably the hype category.
• 30:12
  Speaker 2: And it gets even worse because a lot of people
• 30:15
  Speaker 2: order on Amazon for the convenience, but Amazon mixes all
• 30:20
  Speaker 2: the different people that resent the sell on their site,
• 30:25
  Speaker 2: on their platform, and many of them are Charlatan's so
• 30:28
  Speaker 2: but they're all in this warehouse.
• 30:30
  Speaker 1: So it's you.
• 30:32
  Speaker 2: Know, caution to all people who order supplements on Amazon,
• 30:36
  Speaker 2: because you could be getting something from China that's you know,
• 30:39
  Speaker 2: Chinese people, as we all know, have the amazing ability
• 30:43
  Speaker 2: to imitate and the bottles look the same, you would
• 30:47
  Speaker 2: think you're.
• 30:47
  Speaker 1: Buying right from the manufacturer.
• 30:49
  Speaker 2: So that's another area that you didn't put in here,
• 30:52
  Speaker 2: but it is something for people to be aware of.
• 30:55
  Speaker 4: Yes, very good reminder, Michelle. So this is my supplements
• 31:02
  Speaker 4: in my working area. And so for Wow, yeah, I
• 31:05
  Speaker 4: have a lot of hope. Okay, Wow, you know, I
• 31:08
  Speaker 4: do the investigation and most of these you're not going
• 31:11
  Speaker 4: to find public clinical studies, but it's you know, but
• 31:15
  Speaker 4: they you know logically, you know, if you're talking about
• 31:18
  Speaker 4: like vitamin C, vitamin D, and you know, the common things.
• 31:22
  Speaker 3: So I do a lot of capsules. Now it looks
• 31:24
  Speaker 3: like a massive amount.
• 31:26
  Speaker 4: I don't do more than probably twenty five or thirty
• 31:29
  Speaker 4: capsules a day. I rotate through not only the peptides,
• 31:32
  Speaker 4: but these nutraceuticals. So over the course of the year,
• 31:36
  Speaker 4: my goal is to be able to use these that
• 31:38
  Speaker 4: I think have some you know, reasonable support in terms
• 31:42
  Speaker 4: of being effective along with the peptides. I rotate through
• 31:45
  Speaker 4: all of these during the course of the year.
• 31:47
  Speaker 1: Yes, you know, you know, Bill, sorry to interrupt.
• 31:50
  Speaker 2: You would be so valuable once you get to a
• 31:53
  Speaker 2: point where you feel confident about the results.
• 31:56
  Speaker 1: Even if you don't.
• 31:58
  Speaker 2: Do this as a major study for the world, at
• 32:02
  Speaker 2: least develop a list of bills supplements that work, that
• 32:08
  Speaker 2: are efficacious, and you know, and then give us your source,
• 32:12
  Speaker 2: Like I buy all my stuff on full script.
• 32:15
  Speaker 1: Where do you buy yours?
• 32:17
  Speaker 4: I buy mine from the manufacturers in almost all cases. Yeah,
• 32:22
  Speaker 4: you know, the large nutriceutical companies that have been around.
• 32:26
  Speaker 2: For long time, Like I assume you don't go to
• 32:29
  Speaker 2: Thorn and Designs for Health and the you know, the
• 32:32
  Speaker 2: ones that have the most science.
• 32:34
  Speaker 1: Yeah, okay, well, anyway, I don't want to hold you up.
• 32:37
  Speaker 2: That's that's something I think would be an incredible valuabill.
• 32:41
  Speaker 2: I mean, really, everybody's biochemistry is different, so what might
• 32:45
  Speaker 2: work for you might not work for the next person,
• 32:47
  Speaker 2: particularly if that next person is much more toxic than you.
• 32:51
  Speaker 2: And they so they're taking a supplement, but it's really
• 32:54
  Speaker 2: not getting to where it needs to go because toxicity blockades.
• 32:58
  Speaker 2: But if they do, you follow the other protocols that
• 33:02
  Speaker 2: we're talking about that you propose and expose here for
• 33:07
  Speaker 2: science base, and then you know, are at a point
• 33:10
  Speaker 2: of being receptive to any of these supplements because your
• 33:13
  Speaker 2: body is more is clean or cleaner. Hard to be
• 33:18
  Speaker 2: totally clean in today's world. But anyway, I think that
• 33:22
  Speaker 2: would be an amazing So we'll talk about that offline
• 33:24
  Speaker 2: because I think that's something you should look at.
• 33:27
  Speaker 4: Okay, we will just one added thing to keep me busy, right, and.
• 33:32
  Speaker 2: I know you're not busy enough, Bill, So okay, this
• 33:37
  Speaker 2: is one of the most important bits of information this slide.
• 33:42
  Speaker 3: People don't realize this.
• 33:43
  Speaker 4: I think they realize that animals are used, you know,
• 33:46
  Speaker 4: in the labs for these studies and so forth, principally
• 33:49
  Speaker 4: to determine if there are adverse effects, you know, And
• 33:54
  Speaker 4: what they don't realize is that five percent of the
• 33:58
  Speaker 4: drugs that are processed in a lab and so forth,
• 34:04
  Speaker 4: only about five percent of them work in humans. In
• 34:07
  Speaker 4: other words, percent of the drugs don't work in humans
• 34:12
  Speaker 4: when you try and transfer them over.
• 34:14
  Speaker 3: And it's kind of a yeah, it's kind of a quiet.
• 34:17
  Speaker 4: Secret unfortunately in the pharmaceutical world and even the nutraceutical world.
• 34:24
  Speaker 4: And so you have to be careful when you're looking
• 34:27
  Speaker 4: at an inverseiment, you know, for for let's say a nutraceutical,
• 34:30
  Speaker 4: you need to then dig into it and find out when.
• 34:33
  Speaker 3: Now and by the way, at the bottom of the slide.
• 34:36
  Speaker 4: All these slides, you're going to see the references. These
• 34:40
  Speaker 4: are published clinical studies. On almost every slide that you're
• 34:43
  Speaker 4: going to see is backed by a published clinical study.
• 34:46
  Speaker 4: That's the attorney in.
• 34:47
  Speaker 1: Me, right, And.
• 34:51
  Speaker 2: That was the question I was just about to ask us,
• 34:53
  Speaker 2: where do you get the proof of that? And now
• 34:55
  Speaker 2: I can see down below on my page here that
• 34:58
  Speaker 2: because I made a copy of your entire show, so
• 35:01
  Speaker 2: I'm looking at the hard copy here and yeah, I
• 35:03
  Speaker 2: see now that you have references to you and those
• 35:07
  Speaker 2: studies are proven. I mean, those are I mean, because
• 35:12
  Speaker 2: that always begs the question, how do you know the
• 35:15
  Speaker 2: studies are from people who are don't have special interests.
• 35:20
  Speaker 4: Yeah, these are evidence based, published studies pretty much on
• 35:24
  Speaker 4: every slide that you're going to see. The issue here
• 35:29
  Speaker 4: is that if the failure rate in terms of animal
• 35:33
  Speaker 4: versus human is ninety five percent and only five percent
• 35:37
  Speaker 4: of it works in humans, most of the time, the
• 35:40
  Speaker 4: claims that people are making marketing and so forth, they
• 35:44
  Speaker 4: don't tell you this is based on an animal study.
• 35:46
  Speaker 4: They just say sixty six percent effective and fifty five
• 35:50
  Speaker 4: percent effective. Yeah, in animals, but it's not true in humans,
• 35:55
  Speaker 4: So you have to be really, really careful.
• 35:58
  Speaker 1: Thank you for that. Bill.
• 36:01
  Speaker 4: We'll skip through this kind of quickly. This is what
• 36:04
  Speaker 4: we call the evidence hierarchy. Okay, this is the attorney
• 36:07
  Speaker 4: in me. We have different levels of what we call evidence. Okay,
• 36:13
  Speaker 4: So the number one down here is what we call
• 36:15
  Speaker 4: cell studies and animal models, and that is probably where
• 36:19
  Speaker 4: ninety five percent or more of the marketing and the
• 36:23
  Speaker 4: nutraceuticals and various things. Where they are is that they've
• 36:27
  Speaker 4: either got some cell evidence or they got some animal evidence.
• 36:30
  Speaker 4: And that's the lowest level of what we call evidence.
• 36:33
  Speaker 4: The second one is what we call mechanistic plausibility. In
• 36:36
  Speaker 4: other words, from a biological standpoint, knowing the pathways and
• 36:39
  Speaker 4: so forth, does the intervention make some sense? Like, for instance,
• 36:43
  Speaker 4: if it's lowing blood pressure, do you see an improvement
• 36:46
  Speaker 4: in the arterial system and so can you measure it
• 36:49
  Speaker 4: and so does it make sense? The third level is
• 36:52
  Speaker 4: what we call the observational human data. That's where I
• 36:55
  Speaker 4: am with my two clinical studies. Are you running human
• 36:59
  Speaker 4: studies for long enough? Ours are ten ten years basically
• 37:03
  Speaker 4: where you can observe You may not have a control group,
• 37:06
  Speaker 4: but you can observe like, for instance, Michelle, your labs
• 37:10
  Speaker 4: that we were talking about, the generation labs. Can you
• 37:12
  Speaker 4: observe information that supports the idea that this intervention is
• 37:19
  Speaker 4: having positive results. It's an observational humans data. The problem
• 37:23
  Speaker 4: with we've spent two million dollars in the last ten
• 37:27
  Speaker 4: years on our studies the telomeres and the epigenetics, and
• 37:32
  Speaker 4: we don't have a separate control group because that would
• 37:35
  Speaker 4: increase the cost to like ten million dollars if you
• 37:38
  Speaker 4: had a pro you had a group of people who
• 37:43
  Speaker 4: were taking the peptides versus a group of people taking
• 37:47
  Speaker 4: a non peptide substance. Yeah very siabo, Yeah, very expensive.
• 37:53
  Speaker 4: Then on top of that you get interventional human trials
• 37:56
  Speaker 4: in other words, trials where you actually have a control group.
• 38:01
  Speaker 4: It's a long enough period, you know, months is not
• 38:04
  Speaker 4: is nothing, Okay, we're talking about You've got to have
• 38:07
  Speaker 4: years of success with the control group not benefiting and
• 38:12
  Speaker 4: the group, the group using the intervention are showing success.
• 38:18
  Speaker 3: That takes a long time, it costs a lot of money.
• 38:21
  Speaker 4: And then on top of that you have to also
• 38:24
  Speaker 4: have the number five what we call replication and outcomes
• 38:27
  Speaker 4: in other words, one clinical study published someplace is not enough.
• 38:32
  Speaker 4: You've got to have independent other clinical studies confirming that
• 38:37
  Speaker 4: original study. And one of the criticisms that are made
• 38:42
  Speaker 4: of the Russian so long is that they haven't had
• 38:45
  Speaker 4: a lot of replication studies outside of Russia. I'm going
• 38:48
  Speaker 4: to show that that's incorrect. But that's the gold standard,
• 38:51
  Speaker 4: is when you have multiple clinical studies confirming the benefit
• 38:56
  Speaker 4: of that particular intervention.
• 39:00
  Speaker 3: Okay, longevity science.
• 39:01
  Speaker 4: Here, we're going to talk about the intervention that actually
• 39:04
  Speaker 4: have science behind them to a greater or lesser lesser degree,
• 39:08
  Speaker 4: and there's about nine of them altogether. Mental attitude and
• 39:14
  Speaker 4: what we're showing I need to also talk about mortality
• 39:17
  Speaker 4: risk because longevity studies, of course last a long long time,
• 39:22
  Speaker 4: you know, the lifetime of people.
• 39:24
  Speaker 3: What we do often is we look at.
• 39:26
  Speaker 4: The risk reduction mortality risk reduction of groups of people
• 39:31
  Speaker 4: and assume that that is supporting longevity, and it gets
• 39:34
  Speaker 4: kind of overlapped and a little gray area between when
• 39:38
  Speaker 4: you're talking about mortality risk versus just longevity.
• 39:42
  Speaker 3: But what we know is that these.
• 39:44
  Speaker 4: Interventions that I'm going to show you will reduce mortality.
• 39:48
  Speaker 4: And if it's reducing mortality, then you're getting to some
• 39:51
  Speaker 4: extent longevity. Now, it's not as much longevity as my
• 39:55
  Speaker 4: criteria that I've indicated is what I use and the
• 40:00
  Speaker 4: work that I'm doing. But so, for instance, mental attitude,
• 40:04
  Speaker 4: and these you see the number the letters and the
• 40:06
  Speaker 4: numbers at the bottom PMID. These are the clinical studies
• 40:09
  Speaker 4: published that support all of these. So mental attitude fifteen
• 40:14
  Speaker 4: to twenty percent mortality reduction. If you just think right
• 40:17
  Speaker 4: about your health, if you think I'm going to live
• 40:19
  Speaker 4: a long time, I'm healthy and so forth. Really an
• 40:22
  Speaker 4: interesting story. The actor Morgan Freeman was asked a couple
• 40:28
  Speaker 4: of years ago, and I think he's like eighty nine
• 40:31
  Speaker 4: or ninety at this point, and he's still making movies,
• 40:33
  Speaker 4: and he was asked by somebody something about how is
• 40:38
  Speaker 4: it that you're so healthy, and his response was, I
• 40:42
  Speaker 4: just don't let the old man in. M H.
• 40:45
  Speaker 1: That's great. I saw I saw that interview. Yeah that's great.
• 40:49
  Speaker 4: Yeah, I think that's wonderful. And that's the mental attitude.
• 40:53
  Speaker 4: I have this mental attitude for most of my life
• 40:56
  Speaker 4: that I don't get sick.
• 40:57
  Speaker 3: I never get sick.
• 40:59
  Speaker 4: I haven't had a cold and flu in forty years,
• 41:02
  Speaker 4: maybe a couple of sniffles.
• 41:04
  Speaker 3: But that's it.
• 41:05
  Speaker 4: I've never been inside of a hospital for treatment for me.
• 41:08
  Speaker 4: I haven't seen a conventional doctor in at least forty
• 41:11
  Speaker 4: five years anyway. Then the rest of these are pretty obvious.
• 41:15
  Speaker 4: Sleep thirty nine percent mortality reduction if you're doing proper
• 41:19
  Speaker 4: seven to eight hours of sleep and so forth. Sauna
• 41:22
  Speaker 4: is particularly up in the Scandinavian countries. Almost every home
• 41:28
  Speaker 4: up there automatically, if you like in America, if you
• 41:31
  Speaker 4: have an extra bathroom in Scandinavia, you have a sauna,
• 41:35
  Speaker 4: I mean, just part of their culture. Forty percent mortality
• 41:40
  Speaker 4: risk reduction for people who are using a suna three
• 41:43
  Speaker 4: to four times a week.
• 41:46
  Speaker 3: And then we have the.
• 41:47
  Speaker 4: Blue Zone lifestyle. Everyone's heard of the Blue zones. Those
• 41:51
  Speaker 4: are certain sections of the world, like Sardinia, Okinawa. Actually
• 41:55
  Speaker 4: one is considered to be in California in the United
• 41:58
  Speaker 4: States of low Melenda.
• 42:00
  Speaker 1: That's right.
• 42:00
  Speaker 2: I was just I was just telling someone that yesterday
• 42:03
  Speaker 2: that we only have one.
• 42:05
  Speaker 4: Yeah, it's yeah, it's the what's the Jehovah's Witnesses?
• 42:13
  Speaker 3: Is that who it is?
• 42:14
  Speaker 1: I can't remember.
• 42:15
  Speaker 2: I was trying to tell this gentleman yesterday, what is
• 42:17
  Speaker 2: the name of the like, it's not a Quaker and
• 42:20
  Speaker 2: it's not.
• 42:20
  Speaker 1: I don't think it's Jehovah's Witness's something.
• 42:22
  Speaker 2: There's another practice, a religious practice that you know they
• 42:26
  Speaker 2: are at long we'll we'll look it up afterwards, Bill,
• 42:29
  Speaker 2: But I know, I don't think it's Jehovah Witness.
• 42:32
  Speaker 1: I'm pretty sure.
• 42:32
  Speaker 3: No, you're You're right, it's not. They're vegetarians.
• 42:35
  Speaker 1: I remember exactly. That's just what I told them.
• 42:38
  Speaker 2: I said, I know they're vegan or vegetarian, but I
• 42:40
  Speaker 2: can't remember the name. And I meant to look that
• 42:43
  Speaker 2: up this morning. It's so funny that you brought it up,
• 42:46
  Speaker 2: but I will get it for us.
• 42:48
  Speaker 4: Yeah, And now there's some issues here because the problem
• 42:54
  Speaker 4: was that was the data gathering. They were looking at
• 42:57
  Speaker 4: these different places like Sardinia, Oakland and so forth, and
• 43:02
  Speaker 4: unfortunately a lot of them didn't have really good data
• 43:04
  Speaker 4: evidence like birth certificates and things of that nature. And
• 43:09
  Speaker 4: these are basically kind of small towns that are actually
• 43:11
  Speaker 4: mostly villages where people have lived in that village for
• 43:15
  Speaker 4: generations and they've got three and four generations alive, and
• 43:19
  Speaker 4: you know, and they're close knited and so forth, and
• 43:21
  Speaker 4: so some of the information was based on people recollecting
• 43:24
  Speaker 4: when grandma or great grandma was born, so we can't
• 43:28
  Speaker 4: rely on it one percent, but there's enough information that
• 43:32
  Speaker 4: indicating that in a blue zone type of lifestyle and
• 43:36
  Speaker 4: where we and what we know.
• 43:37
  Speaker 3: That's a really important part of that.
• 43:39
  Speaker 4: Is the socialization the people around you that are going
• 43:42
  Speaker 4: to be around you for your whole life. Of the
• 43:45
  Speaker 4: three generations living in the maybe the same home and
• 43:48
  Speaker 4: certainly with with you know, a short distance of each other,
• 43:52
  Speaker 4: thirty to fifty percent mortality reduction.
• 43:55
  Speaker 2: Well, it goes back to about you know, the five pillars,
• 43:58
  Speaker 2: and you've you know, so you're covering those and a
• 44:01
  Speaker 2: lot of times people miss that fifth pillar, which is,
• 44:04
  Speaker 2: you know the importance of relationships and connectivity to community
• 44:08
  Speaker 2: and love. I mean just having love in your life
• 44:12
  Speaker 2: from you know, doesn't always have to be romantic.
• 44:15
  Speaker 1: It can be family love or you know, just the.
• 44:19
  Speaker 2: Love and passion of being alive, but feeling that connectivity
• 44:24
  Speaker 2: to others. And yeah, so that's a very important one, Bill,
• 44:28
  Speaker 2: I'm glad you brought that up.
• 44:30
  Speaker 4: Yes, And unfortunately, because the way we live today in America,
• 44:35
  Speaker 4: it's reflected by the lifespan numbers, the health span numbers
• 44:39
  Speaker 4: that are really kind of, you know, sad compared to
• 44:42
  Speaker 4: the rest of the world, because we've lost a lot
• 44:44
  Speaker 4: of this bluestone lifestyle. It's very rare to have various
• 44:49
  Speaker 4: generations when people are older, still living together, even in
• 44:53
  Speaker 4: the same town. So then we get to peptide bio regulators,
• 44:58
  Speaker 4: and I'm going to spend a lot more time towards
• 45:00
  Speaker 4: the end of this talking about that. The mortality risk
• 45:03
  Speaker 4: reduction is thirty three percent, and we'll skip over it
• 45:06
  Speaker 4: for the detail because I'm going to get to it.
• 45:08
  Speaker 4: Then clerk restriction significant ten to fifteen percent reduction, exercise
• 45:16
  Speaker 4: thirty to forty five percent reduction. Now what this is,
• 45:23
  Speaker 4: This is my wife, wonderful wife, Visa and I. Married
• 45:26
  Speaker 4: men have a thirty one percent decreased all cause mortality
• 45:30
  Speaker 4: risk compared to unmarried men.
• 45:32
  Speaker 3: Wow, but look at the women.
• 45:35
  Speaker 4: Married women have an eighteen percent decrease all cause mortality
• 45:40
  Speaker 4: risk compared to unmarried women. In other words, the men
• 45:43
  Speaker 4: have a lot less longevity than the women. Handling being single,
• 45:50
  Speaker 4: You could say.
• 45:51
  Speaker 1: So what do you think, what do you think is
• 45:53
  Speaker 1: the message out of that?
• 45:55
  Speaker 4: Oh, the messages women take care of themselves and women
• 45:58
  Speaker 4: have communities, they are.
• 46:00
  Speaker 3: More social than men.
• 46:01
  Speaker 4: That's a lot a lot of it, but mostly is
• 46:04
  Speaker 4: that they're just typically. That's why I think the gap
• 46:08
  Speaker 4: was what the seven years between the men and the
• 46:10
  Speaker 4: women in the US, the women had about it, Yeah,
• 46:13
  Speaker 4: because they just take.
• 46:14
  Speaker 3: Care of themselves better, right, And you know, there's.
• 46:17
  Speaker 4: Also issues like how much stress do men undergo in
• 46:20
  Speaker 4: a lifetime versus women and.
• 46:22
  Speaker 2: All that stuff, right, And lifestyle choices like the food
• 46:26
  Speaker 2: that they choose and the alcohol and drug.
• 46:29
  Speaker 1: Use and stuff with I think is another Those are
• 46:31
  Speaker 1: other factors.
• 46:32
  Speaker 2: Too, But you're right, the overall truth is that women
• 46:37
  Speaker 2: are more conscious.
• 46:39
  Speaker 1: Sorry to say, but.
• 46:41
  Speaker 4: Yeah, and then on top of that, if you get
• 46:44
  Speaker 4: a dog, you get another twenty four percent reduction and
• 46:47
  Speaker 4: all cause mortality risks.
• 46:49
  Speaker 2: WHOA.
• 46:50
  Speaker 1: Now that's an interesting fact. I didn't know.
• 46:54
  Speaker 4: And you can see the clinical here, the PMID. It's
• 46:58
  Speaker 4: based on the clinical study. So Ves, we've been together
• 47:02
  Speaker 4: sixteen plus years at this point. When I was putting
• 47:05
  Speaker 4: this together and showing it two or some months ago,
• 47:08
  Speaker 4: she looked at me and she said, so, did you
• 47:11
  Speaker 4: marry me as part of your longevity program? And I said,
• 47:15
  Speaker 4: of course, not dear, but let's get a dog.
• 47:19
  Speaker 1: That's great.
• 47:21
  Speaker 3: Oh this okay.
• 47:22
  Speaker 4: As you can tell, I'm very passionate and devoted and
• 47:26
  Speaker 4: even obsessed what Ves says about my longevity and my health.
• 47:30
  Speaker 4: And so I put this one in here because cloric
• 47:32
  Speaker 4: restriction is really powerful.
• 47:35
  Speaker 3: So this is Ves.
• 47:36
  Speaker 4: And this is me taking it my cloric restriction to
• 47:40
  Speaker 4: an extreme.
• 47:41
  Speaker 3: You might say, well, you.
• 47:43
  Speaker 2: Know I've had doctor anton On. He's the interbitten fasting
• 47:49
  Speaker 2: with food, so it's called prolonged health. And you know,
• 47:53
  Speaker 2: I told him, Hey, I do intermittent fashion because I
• 47:56
  Speaker 2: do it at night because it's so easy. You go
• 47:58
  Speaker 2: to bet, you stop eating at seven and you don't
• 48:00
  Speaker 2: eat again till eleven the next day, and now you've
• 48:02
  Speaker 2: done your fast and it doesn't really affect you at
• 48:05
  Speaker 2: all except maybe those first few hours. But those are
• 48:08
  Speaker 2: the hours that I'm usually doing things like, you know,
• 48:11
  Speaker 2: planning my day, exercising, things that you don't really miss
• 48:15
  Speaker 2: that you know, first morning thing.
• 48:18
  Speaker 1: So he said, oh, Michelle, that's all wrong.
• 48:21
  Speaker 2: You should only do sixteen hours max. And so I
• 48:24
  Speaker 2: don't know, what do you feel? What's your number that
• 48:27
  Speaker 2: you use for your your intermittent fasting.
• 48:31
  Speaker 4: I don't think that there's a solid gold number. You know,
• 48:35
  Speaker 4: we have different physiologies and so forth. What I do,
• 48:38
  Speaker 4: and I don't think it makes too much difference an
• 48:40
  Speaker 4: hour or two. Is I start eating at ten in
• 48:43
  Speaker 4: the morning, I stop at five o'clock.
• 48:45
  Speaker 3: Yeah, But I also though.
• 48:48
  Speaker 4: I stop eating at five o'clock on Thursday night, and
• 48:52
  Speaker 4: then I don't have any food until Saturday morning around
• 48:55
  Speaker 4: nine or ten. So it gives you about a thirty
• 48:57
  Speaker 4: five to thirty six continuous fasting and I've done that
• 49:01
  Speaker 4: for years.
• 49:02
  Speaker 1: Well, I congratulate you. I think it's so hard, particularly
• 49:06
  Speaker 1: when you're active and.
• 49:09
  Speaker 2: You know, but I that's why I do the night
• 49:12
  Speaker 2: one because it doesn't affect me at all.
• 49:14
  Speaker 1: But yeah, I congratulate you for doing that one day
• 49:19
  Speaker 1: or a thirty five hour fast.
• 49:23
  Speaker 4: Well, I think from my experience, the reason that people
• 49:26
  Speaker 4: have your program is excellent because you're as you say,
• 49:31
  Speaker 4: as you've identified, there's only a few hours where you
• 49:34
  Speaker 4: might be you know, people might be eating because you're
• 49:37
  Speaker 4: sleeping so much. If that's a great first. I think
• 49:39
  Speaker 4: initial step for most people where people I think run
• 49:43
  Speaker 4: into problems is all of a sudden they decide okay,
• 49:47
  Speaker 4: I've got to do this fasting intermittent fasting thing. And
• 49:51
  Speaker 4: they set out the time and so forth, and after
• 49:54
  Speaker 4: a few days it just doesn't work for them because
• 49:56
  Speaker 4: they've bitten off too much at this point. So what
• 49:58
  Speaker 4: I tell people is no, just to add thirty minutes
• 50:01
  Speaker 4: or an hour the first week eliminature, yeah, and then
• 50:06
  Speaker 4: the second week two hours, and you'll kind of ease
• 50:09
  Speaker 4: yourself into this. And so for me, the thirty five
• 50:12
  Speaker 4: hours or so is simple. I've been doing it for
• 50:14
  Speaker 4: so long, so don't know.
• 50:16
  Speaker 2: You know, and it's become a routine for you. So
• 50:18
  Speaker 2: you know, some things that you do repeatedly. It's the
• 50:21
  Speaker 2: old story about experience, you know, the experiential side, that
• 50:25
  Speaker 2: you keep doing something as it becomes a habit, and
• 50:29
  Speaker 2: the habit becomes you don't even.
• 50:30
  Speaker 1: Have to think about it. It's just normal behavior. So
• 50:34
  Speaker 1: that's I think how.
• 50:35
  Speaker 2: It explains what you know, you've been successful doing they
• 50:38
  Speaker 2: fasting like that because you've just done it for so long.
• 50:42
  Speaker 3: It's yeah, that's true.
• 50:44
  Speaker 4: I weighed today the same as I waited in high school,
• 50:48
  Speaker 4: and it's a lot of it. And at one point,
• 50:49
  Speaker 4: when I was practicing a law, I was probably let
• 50:53
  Speaker 4: me think, twenty five pounds heavier at that.
• 50:57
  Speaker 1: Probably some really bad eating habits too.
• 51:00
  Speaker 3: Yeah. Yeah.
• 51:01
  Speaker 4: So where we are today is that this slide talks
• 51:03
  Speaker 4: about the billionaires are bake rolling cell retuvenation, and they've
• 51:08
  Speaker 4: come to realize, as I said earlier that it's kind
• 51:12
  Speaker 4: of a crude way of saying it, they've got more
• 51:14
  Speaker 4: money than they've got time left right, and as a result,
• 51:18
  Speaker 4: they're funding. In fact, I have a slide here, they're
• 51:21
  Speaker 4: funding all of these what I call crossing the bridge
• 51:25
  Speaker 4: that I'll talk about in a moment.
• 51:26
  Speaker 3: But all of.
• 51:26
  Speaker 4: These interventions like quantum computers, artificial intelligence is already here, Crisper,
• 51:32
  Speaker 4: that's the cutting you on, the genome, gene sequencing, stem cells,
• 51:37
  Speaker 4: replacement organs. All of these things are being funded these
• 51:41
  Speaker 4: days in order to be able to extend their life.
• 51:44
  Speaker 4: And these are some of the companies over here on
• 51:46
  Speaker 4: the right, Calibo and so forth. The investment this slide
• 51:51
  Speaker 4: is a little old. I'm sure the investment now is
• 51:53
  Speaker 4: over twenty to twenty five.
• 51:54
  Speaker 1: Billion, Oh for sure.
• 51:56
  Speaker 2: I mean Brian Johnson just as an individual says he's
• 52:00
  Speaker 2: two million a year, and then you know you've got
• 52:03
  Speaker 2: Jeff Bezos and Peter Thiel and you know David Sinclair. Yeah,
• 52:09
  Speaker 2: there's there is so much more than ten billion right now,
• 52:13
  Speaker 2: but I don't know what the number is, but it
• 52:15
  Speaker 2: would be interesting to find that out.
• 52:16
  Speaker 1: I think we should ask chat GBT that question.
• 52:21
  Speaker 4: So this is the longevity bridge, what I call the
• 52:25
  Speaker 4: longevity bridge. And this this is dated because I think
• 52:28
  Speaker 4: I put this together about five or six years ago.
• 52:31
  Speaker 4: The idea here, though, is that if we can stay
• 52:36
  Speaker 4: healthy today that imagine ten years from now, what's going
• 52:41
  Speaker 4: to be available to us in the future. All those
• 52:43
  Speaker 4: technologies that I just talked about, crisper and so forth
• 52:47
  Speaker 4: will probably be operational at that point and we'll be
• 52:50
  Speaker 4: able to take advantage of them. But the key is
• 52:53
  Speaker 4: you've got to clean up your life. You've got to
• 52:56
  Speaker 4: do all the healthy things that you can do today
• 52:59
  Speaker 4: in order to be a round in five or ten
• 53:01
  Speaker 4: more years to take advantage of those things.
• 53:04
  Speaker 1: Right.
• 53:05
  Speaker 2: Yeah, that's Peter Diamandis was a speaker at a four
• 53:10
  Speaker 2: M two years ago, and he said, just don't die
• 53:14
  Speaker 2: in the next ten years, because what we've accomplished in
• 53:16
  Speaker 2: the last ten years is more than the last hundred
• 53:19
  Speaker 2: years and the next ten years is going to be
• 53:21
  Speaker 2: even more compelling. So that was a you know, an
• 53:25
  Speaker 2: important message for everybody to take care of yourself or
• 53:28
  Speaker 2: start putting your habits, you know, into the right perspective
• 53:32
  Speaker 2: of practice. And well we've already seen, you know, even
• 53:37
  Speaker 2: though not all of these protocols that you've mentioned our
• 53:41
  Speaker 2: science base, yet we have seen these you know, amazing
• 53:45
  Speaker 2: developments that and here's the next slide. I just see
• 53:49
  Speaker 2: a lifespan by David Sinclair. So I don't want to
• 53:52
  Speaker 2: steal your thunder, but go ahead, not at all.
• 53:55
  Speaker 3: Yeah, I have a lot of respect for mister or
• 53:59
  Speaker 3: doctor Sinclair.
• 54:01
  Speaker 4: He's really leading in this whole longevity health span world.
• 54:09
  Speaker 4: What he's saying here, I'll read it for the people.
• 54:13
  Speaker 3: He says.
• 54:14
  Speaker 4: I have little doubt that sell your reprogramm is the
• 54:16
  Speaker 4: next frontier. You know, all these things and over and
• 54:19
  Speaker 4: then this is the important part. One day it might
• 54:22
  Speaker 4: be possible to reprogram cells by pills and stimulate that
• 54:27
  Speaker 4: stimulate the activity of the os K factors or the TETs.
• 54:34
  Speaker 4: This may be simpler than it sounds. Natural molecules stimulate
• 54:38
  Speaker 4: the tet enzymes, and the tet enzymes are basically a
• 54:41
  Speaker 4: special type of protein. So what he's saying is is
• 54:45
  Speaker 4: it one day pills are going to come along. There
• 54:47
  Speaker 4: will be natural molecules. And I think he wrote the
• 54:51
  Speaker 4: book about five or six years ago. Well, the interesting
• 54:54
  Speaker 4: thing is these peptide bioregulators that I'm going to talk
• 54:58
  Speaker 4: about in a moment do exactly that. They are natural
• 55:01
  Speaker 4: molecules that stimulate everything in the body. They extend, they
• 55:07
  Speaker 4: drive the telomeris that lengthens the telomeres, they drive the
• 55:10
  Speaker 4: epigenetic age reversal. They're capsules that are basically natural molecules.
• 55:17
  Speaker 4: And we'll get into the detail of that. So he
• 55:20
  Speaker 4: was predicting and we now have that. So we turned
• 55:23
  Speaker 4: to Russia at this point, as you mentioned in the introduction, Yes,
• 55:27
  Speaker 4: I went to Russia two thousand and fourteen or fifteen,
• 55:31
  Speaker 4: I think knocked on the door. Now when I say
• 55:34
  Speaker 4: I went, I got interested in what they were doing.
• 55:38
  Speaker 4: When we had Google Translator available, I was seeing some
• 55:41
  Speaker 4: remarkable studies coming out of Russia and when they were translated,
• 55:46
  Speaker 4: so I started reading everything I could get my hands on,
• 55:49
  Speaker 4: and I realized that with these pepti bio regulators, they're
• 55:53
  Speaker 4: doing amazing things that are unheard of in America, and
• 55:56
  Speaker 4: so I sent a series of emails asking and they
• 55:59
  Speaker 4: were very gracious and they said, sure.
• 56:01
  Speaker 3: Come on over.
• 56:02
  Speaker 4: I think they were stunned, you know, I would call
• 56:05
  Speaker 4: myself at that point of research or maybe I'm a
• 56:08
  Speaker 4: scientist now I don't. I'm not sure, but they were
• 56:12
  Speaker 4: just stunned that anybody would from America would pay any
• 56:15
  Speaker 4: attention to what they're doing in Russia, because I think
• 56:18
  Speaker 4: you in your opening comments you indicated they're just very
• 56:21
  Speaker 4: little communication unfortunately between the two countries. And so they thought,
• 56:28
  Speaker 4: you know this guy, what is he what does he
• 56:32
  Speaker 4: want to do? So I showed up this and I
• 56:34
  Speaker 4: showed up. They took us in. We all of us
• 56:37
  Speaker 4: just kind of fell into this mutual friendship thing. And
• 56:41
  Speaker 4: Professor Cavinson, who was pictured on the right here took
• 56:44
  Speaker 4: me in and he was my mentor until he died.
• 56:48
  Speaker 4: Taught me everything that I know about peptide bio regulators. Anyway,
• 56:54
  Speaker 4: this is President putin awarding Professor Cavinson the civilian highest
• 57:00
  Speaker 4: award that they can give for his forty some odd
• 57:02
  Speaker 4: years of service to the Russian people in the area
• 57:06
  Speaker 4: of health, etc. And he is the one that created
• 57:10
  Speaker 4: this what we call the mechanisms of peptide regulation of aging.
• 57:13
  Speaker 4: In other words, we can use peptide bioregulators to regulate
• 57:17
  Speaker 4: the aging process to slow down and more importantly, or
• 57:20
  Speaker 4: at least as importantly, to be able to reverse a
• 57:24
  Speaker 4: lot of characteristics of aging biologically. And I'm going to
• 57:27
  Speaker 4: show you the proof of that. Cavinson's well known all
• 57:32
  Speaker 4: over Europe, hardly known at all here in the United States.
• 57:36
  Speaker 4: He started off in the military many years ago. He
• 57:39
  Speaker 4: was a colonel in the military. He's the author of
• 57:42
  Speaker 4: seven hundred scientific publications and just a powerhouse. He was
• 57:49
  Speaker 4: the chairman of every single gerontology association in Europe at
• 57:55
  Speaker 4: one point.
• 57:58
  Speaker 1: Did he ever get the Nobel Prize or any of
• 58:00
  Speaker 1: his work?
• 58:01
  Speaker 4: No, he was nominated for it and then politics. In
• 58:06
  Speaker 4: that Nobel Prize, three Americans were awarded jointly. The This
• 58:11
  Speaker 4: is in two thousand and nine. They were awarded the
• 58:14
  Speaker 4: Nobel Prize for having quote discovered tulameras that's the enzyme.
• 58:19
  Speaker 2: Yeah, it's used, Okay, Elizabeth whatever from San Francisco.
• 58:24
  Speaker 4: Yeah, yeah, Elizabeth Blackburn and Blackburn yeah, and Thretta I
• 58:29
  Speaker 4: can't remember her name anyway. Three Americans were actually awarded
• 58:34
  Speaker 4: the Nobel Prize for quote discovering tullamras well twenty years
• 58:39
  Speaker 4: before Cavinson discovered it. And when I say Cavinson, he
• 58:43
  Speaker 4: and his institute associates they not only discovered it, but
• 58:47
  Speaker 4: they were using it twenty years before on human beings.
• 58:50
  Speaker 4: So there was a lot of politics and Cavinson, you know,
• 58:53
  Speaker 4: it was entered as a nominee, but they basically ignored
• 58:57
  Speaker 4: the Russian stuff. So we have a discovery, you know,
• 59:02
  Speaker 4: in a lab by the Americans, and then we have
• 59:05
  Speaker 4: over here a guy that's been using that discovery for
• 59:08
  Speaker 4: twenty plus years on humans, and they get the.
• 59:13
  Speaker 2: Well, we has Donald Trump. It's totally politicized.
• 59:18
  Speaker 3: Yeah. Yeah.
• 59:20
  Speaker 4: So what this shows, Michelle is people say, well, but
• 59:23
  Speaker 4: that's all that Russian stuff, you know, we don't. That's
• 59:27
  Speaker 4: just not true at all. These are the institutions that
• 59:31
  Speaker 4: worked with Cabinis and over the years jointly and so
• 59:34
  Speaker 4: including the National Institute of Aging here in the United States,
• 59:38
  Speaker 4: the Italian National Research Center, the German University of Munich, Spain, Belgium,
• 59:46
  Speaker 4: and sover. They all work together in terms of the
• 59:50
  Speaker 4: development of this peptid bioregulators in the clinical studies. And
• 59:54
  Speaker 4: then on top of that, these are just some of
• 59:57
  Speaker 4: his seven hundred studies. These are the ones that are
• 59:59
  Speaker 4: very civic to peptide bioregulators for mortality, risk reduction and longevity.
• 1:00:05
  Speaker 4: And you know, the year's twenty twenty three, and this
• 1:00:08
  Speaker 4: goes back to nineteen eighty two. These are the published
• 1:00:11
  Speaker 4: studies that he was able to create during all this
• 1:00:15
  Speaker 4: period of time, a lot of it about telomeres, a
• 1:00:17
  Speaker 4: lot about longevity. Yeah, and then this is that criticism about, well,
• 1:00:26
  Speaker 4: but this is just a Russia thing, and so it's.
• 1:00:28
  Speaker 3: Not true at all.
• 1:00:29
  Speaker 4: These are publications outside of Russia that confirm what the
• 1:00:33
  Speaker 4: Russians were doing. So there's what six of these non
• 1:00:37
  Speaker 4: Russian publications clinical studies and so forth. And the one
• 1:00:41
  Speaker 4: here in twenty twenty five is interesting. It's a British
• 1:00:44
  Speaker 4: study that was just published six months or so ago,
• 1:00:49
  Speaker 4: independent of the Russians, completely, you know, basically creating what
• 1:00:54
  Speaker 4: we call telomers and that we're being able to use
• 1:00:57
  Speaker 4: a particular peptide to Lengthen telomeres had no relationship whatsoever.
• 1:01:02
  Speaker 4: And it's like twenty twenty five versus Cabinson's first discovery
• 1:01:06
  Speaker 4: was about nineteen ninety five. I think independent, no connection
• 1:01:12
  Speaker 4: whatsoever between the Russians. Okay, so peptide bioreggs, what are they.
• 1:01:18
  Speaker 4: There's short chains of two to four amino acids. They're
• 1:01:21
  Speaker 4: parts of a protein. Everyone knows what proteins are. We
• 1:01:24
  Speaker 4: get them from our food primarily and then some supplements
• 1:01:27
  Speaker 4: so forth. But what is also possible where the peptides
• 1:01:32
  Speaker 4: come from, is that there is a division made in
• 1:01:35
  Speaker 4: sort of the biological scientific field in terms of the
• 1:01:38
  Speaker 4: size of these things. And what we're looking at is
• 1:01:41
  Speaker 4: chains of amino acids. So if you have a big protein,
• 1:01:44
  Speaker 4: it's typically fifty amino acids or more, and some of
• 1:01:47
  Speaker 4: them are like a thousand on that chain. If you
• 1:01:50
  Speaker 4: have a what we call a peptide, it simply is
• 1:01:53
  Speaker 4: a protein, but it's a very small chain or collection
• 1:01:57
  Speaker 4: of whatever the substance is the amino acid. These peptides
• 1:02:01
  Speaker 4: come from animals. They're extracted from animals and tissues of animals.
• 1:02:05
  Speaker 4: And while people think that that's strange today, for the
• 1:02:09
  Speaker 4: entire history of human beings, until probably maybe one hundred
• 1:02:13
  Speaker 4: and fifty maybe two hundred years ago, medicine as we know,
• 1:02:19
  Speaker 4: it was basically obtained from animals and plants. I mean,
• 1:02:23
  Speaker 4: that's where the pharmaceutical world started from. For hundreds of
• 1:02:27
  Speaker 4: thousands of years, were animals and plants. And so what
• 1:02:31
  Speaker 4: Cabinsen did was simply rotate back, you might say.
• 1:02:36
  Speaker 3: And what they create.
• 1:02:38
  Speaker 4: The source of these are organs from pigs and calves,
• 1:02:42
  Speaker 4: and they process them into amino acid chains and then
• 1:02:48
  Speaker 4: they put them basically into human beings, either by injection
• 1:02:52
  Speaker 4: or oral capsules. And what they do is they rejuvenate
• 1:02:57
  Speaker 4: human organs and systems literally. And I've seen this so
• 1:03:00
  Speaker 4: many times, and I'm going to show a couple of
• 1:03:02
  Speaker 4: slides in the vision field that shows that rejuvenation. They
• 1:03:06
  Speaker 4: extend telomeres, they activate genes for cell regeneration, gene expression,
• 1:03:11
  Speaker 4: DNA methylation. Let's talk quickly about the hateflick commit. We
• 1:03:17
  Speaker 4: could spend an hour just explaining the hatef flick limit.
• 1:03:20
  Speaker 4: Leonard Hayflick, wonderful scientist think UC Berkeley, I believe, unfortunately
• 1:03:27
  Speaker 4: died just a couple of years ago, maybe four or
• 1:03:29
  Speaker 4: five years ago, in the fifties, he figured out using
• 1:03:34
  Speaker 4: cell tracking, you might say that a human well, let
• 1:03:38
  Speaker 4: me back up we're alive today because we have cell replication.
• 1:03:42
  Speaker 4: All of our cells are replicating all the time over
• 1:03:45
  Speaker 4: a lifetime, and it's that cell replation that keeps the
• 1:03:49
  Speaker 4: biologic running, everything sort of more or less working. But
• 1:03:54
  Speaker 4: he found that there was only so many divisions of
• 1:03:58
  Speaker 4: these cells, and after a certain number of divisions that
• 1:04:02
  Speaker 4: the tea limbers get very short and the cells stop dividing,
• 1:04:05
  Speaker 4: and at that point you get what we call sin
• 1:04:07
  Speaker 4: essence cells that are dying off. That can actually be
• 1:04:11
  Speaker 4: somewhat problematic at times. So the span basically is that
• 1:04:16
  Speaker 4: most normal human cells can divide about forty to sixty times.
• 1:04:21
  Speaker 4: A relook at his materials suggests it could be even
• 1:04:24
  Speaker 4: as many as seventy times. So we have the ability
• 1:04:28
  Speaker 4: to replicate those cells about say forty fifty sixty times,
• 1:04:35
  Speaker 4: important for continuing life. Okay, Well, Cabinson figured out and
• 1:04:42
  Speaker 4: published a study in two thousand and four that the
• 1:04:45
  Speaker 4: peptide promotes overcoming of the division limit in human somatic cells.
• 1:04:50
  Speaker 4: In other words, what he discovered and published is that
• 1:04:53
  Speaker 4: with these peptides that he could get more cell replication
• 1:04:57
  Speaker 4: than what was done under the Hayflick climb. And I
• 1:05:00
  Speaker 4: sent this to Leonard Hayflick about seven eight years ago
• 1:05:03
  Speaker 4: this study. Unfortunately, never heard back from him. I guess
• 1:05:08
  Speaker 4: he was probably a busy guy, but this was you know,
• 1:05:12
  Speaker 4: this is like like Nobel Prize twice of importance. I mean,
• 1:05:16
  Speaker 4: if you can extend the number of cell replications, and
• 1:05:20
  Speaker 4: I think I show it here. Yeah, without getting all
• 1:05:23
  Speaker 4: the detail of all this. If you look at the
• 1:05:25
  Speaker 4: blue line at the top, that's what that's the peptide
• 1:05:29
  Speaker 4: of pitulawn. And what they're showing at the top of
• 1:05:33
  Speaker 4: the blue is an increase in the cell replications. What
• 1:05:36
  Speaker 4: they're showing in the darker line that's slanting downward is
• 1:05:40
  Speaker 4: the natural slowing down of the replication in human beings.
• 1:05:45
  Speaker 4: And what the bar chart is showing here at the bottom,
• 1:05:48
  Speaker 4: naturally they have a cell replication in this study of
• 1:05:52
  Speaker 4: about fifty four times the book called Doublings, when you
• 1:05:56
  Speaker 4: add the pittolawn peptide bioregular into it, you get one
• 1:06:01
  Speaker 4: hundred and four doubling compared to fifty four. That is
• 1:06:07
  Speaker 4: remarkable extension of life. And we can't really quantify it
• 1:06:13
  Speaker 4: in terms of years, but it's somewhere in the magnitude
• 1:06:16
  Speaker 4: of probably twenty five to thirty percent additional overall cell replication.
• 1:06:22
  Speaker 4: And not only does that support longevity, but if you
• 1:06:25
  Speaker 4: have new cells being replicated all the time, you're starting
• 1:06:28
  Speaker 4: off with brand new, infancy kind of cells that are healthy.
• 1:06:34
  Speaker 3: So you're continuing to feed your.
• 1:06:36
  Speaker 4: Replication instead of using the cell replication to say, fifty
• 1:06:41
  Speaker 4: times and those start to peter out. You're getting constantly
• 1:06:44
  Speaker 4: a lot more of these new cells.
• 1:06:47
  Speaker 2: And do you feel there's a difference between taking them
• 1:06:50
  Speaker 2: orally and injecting epitol on?
• 1:06:53
  Speaker 3: Do I feel it or do I know if there's
• 1:06:55
  Speaker 3: no I mean.
• 1:06:55
  Speaker 2: Do you believe that there is a difference because some
• 1:06:59
  Speaker 2: people well are injecting and others like me are using
• 1:07:04
  Speaker 2: your product pitle on that you you provide. If you
• 1:07:08
  Speaker 2: feel there's any any difference in the outcome.
• 1:07:11
  Speaker 3: There's a slight difference.
• 1:07:12
  Speaker 4: Cavinsen did a clinical study of published clinical studies probably
• 1:07:16
  Speaker 4: twenty years ago, where he was comparing the injectable pitle
• 1:07:21
  Speaker 4: on okay to the synthetic pit epiit.
• 1:07:26
  Speaker 3: I'm sorry epitalman is.
• 1:07:28
  Speaker 2: I was wondering about the pronunciation built too, because I
• 1:07:31
  Speaker 2: had always always heard epiitalon. But then when you said
• 1:07:33
  Speaker 2: a pitolean. I said, I get I guess I better
• 1:07:36
  Speaker 2: say it right the way Bill does. So which way
• 1:07:38
  Speaker 2: is the right way?
• 1:07:39
  Speaker 4: Well, there's no right way. It's just you know, it's
• 1:07:41
  Speaker 4: that tomato tomato kind of thing. Yeah, anyway, to answer
• 1:07:44
  Speaker 4: your question, we in the clinical study we use the
• 1:07:48
  Speaker 4: oral castles.
• 1:07:49
  Speaker 3: Okay.
• 1:07:50
  Speaker 4: In Russia they used mostly the injections. Cavinsen did us
• 1:07:54
  Speaker 4: a telomere study twenty some odd years ago to compare
• 1:07:58
  Speaker 4: the two in terms of how my which telomers would
• 1:08:01
  Speaker 4: be activated at the enzyme and what the result would
• 1:08:04
  Speaker 4: be in terms of telomere length. The difference between using
• 1:08:07
  Speaker 4: the injectible and this was a five year study, I
• 1:08:10
  Speaker 4: think the difference between using the injectible, okay versus the
• 1:08:14
  Speaker 4: old capsules was eight percent in terms of in terms
• 1:08:19
  Speaker 4: of length. So the answer is, yeah, small difference, but
• 1:08:22
  Speaker 4: most people would prefer to take the capsules then be injected.
• 1:08:26
  Speaker 4: And these are not the sub q in you know,
• 1:08:28
  Speaker 4: these are intermuscular injections with an ech and a half, you.
• 1:08:31
  Speaker 1: Know, cause they hurt more.
• 1:08:34
  Speaker 3: Yeah they do, Yeah, they do. Okay.
• 1:08:37
  Speaker 4: So another published clinical study in two thousand and three,
• 1:08:42
  Speaker 4: peptides of the pineal gland and famous prolonged human life.
• 1:08:46
  Speaker 4: This is dramatic because we're looking at a period of
• 1:08:51
  Speaker 4: time of up to twelve years. The study around, we're
• 1:08:54
  Speaker 4: looking at mortality reduction, which is kind of a proxy
• 1:08:57
  Speaker 4: for longevity, people living longer. And what he did was
• 1:09:01
  Speaker 4: he had several groups of older people broken down by age,
• 1:09:06
  Speaker 4: and he then had a control group not using the peptides,
• 1:09:09
  Speaker 4: and then he had a group just using the peptides.
• 1:09:13
  Speaker 4: And this chart here that I created. He had this
• 1:09:17
  Speaker 4: group called eldert people age sixty to seventy four. They
• 1:09:20
  Speaker 4: were to control people what we call using poly vitamins,
• 1:09:26
  Speaker 4: just regular things that you would have. And if we
• 1:09:29
  Speaker 4: go down to the mortality rate in the course of
• 1:09:32
  Speaker 4: twelve years, right in.
• 1:09:33
  Speaker 3: The middle of that, okay, if we look at.
• 1:09:34
  Speaker 4: The results over twelve years, forty four percent of the
• 1:09:39
  Speaker 4: people in the control group, the non peptide group had died.
• 1:09:43
  Speaker 3: Okay.
• 1:09:44
  Speaker 4: On the other hand, the next call him over the
• 1:09:47
  Speaker 4: administration of the pineal gland. In other wards, one peptide,
• 1:09:51
  Speaker 4: the pineal gland peptide. Look at the death rate, it's
• 1:09:54
  Speaker 4: half of that of the control group. It's twenty two percent.
• 1:09:58
  Speaker 4: In other words, using over a period of twelve years,
• 1:10:01
  Speaker 4: the peptide reduced the death rate or the mortality rate
• 1:10:04
  Speaker 4: by fifty.
• 1:10:07
  Speaker 3: I don't know of anything out there that will do that.
• 1:10:11
  Speaker 2: And how often we study bill, how often did the
• 1:10:16
  Speaker 2: if they were using the epitol on, how often did
• 1:10:20
  Speaker 2: they have to take it.
• 1:10:21
  Speaker 1: Throughout that year in order to have that kind of outcome.
• 1:10:25
  Speaker 4: They only took the peptide for the first three years
• 1:10:28
  Speaker 4: in the twelve year study, first three years, and only
• 1:10:32
  Speaker 4: limited amount maybe let's just say monthly for maybe ten
• 1:10:38
  Speaker 4: or fifteen days, but only the first three years, and
• 1:10:42
  Speaker 4: then no further use to the peptide for the next
• 1:10:45
  Speaker 4: nine years.
• 1:10:46
  Speaker 1: That's staggering.
• 1:10:48
  Speaker 4: Yeah, it talks to the fact that these peptides were
• 1:10:52
  Speaker 4: able to regenerate the organs and the systems such that
• 1:10:56
  Speaker 4: when they regenerated them, let's say in year three or four,
• 1:11:00
  Speaker 4: then for umpteen years later, this is the death reduction half.
• 1:11:04
  Speaker 4: Now let's go to the next group, the group I'm in.
• 1:11:08
  Speaker 3: They call it the old people. The Russians aren't diplomatic.
• 1:11:11
  Speaker 2: That's pretty that's pretty discouraging because you're not old.
• 1:11:15
  Speaker 1: But anyway, they got to come up with a different name.
• 1:11:18
  Speaker 3: Yeah, Well that's the Russians.
• 1:11:20
  Speaker 4: I mean, I love those people, but yeah, they're just
• 1:11:22
  Speaker 4: sometimes not as diplomatic as you're.
• 1:11:24
  Speaker 2: Not not diplomatic, right, So old people, yeah, seventy five
• 1:11:28
  Speaker 2: to eighty nine.
• 1:11:29
  Speaker 4: Yeah, and I'm in the middle of that group. I'm
• 1:11:31
  Speaker 4: going to be eighty in a few weeks. So they
• 1:11:35
  Speaker 4: had been a control group again poly vitamins, and during
• 1:11:38
  Speaker 4: that looking at the bottom of the course of six years.
• 1:11:41
  Speaker 4: It was a shorter study of course because the people
• 1:11:43
  Speaker 4: were older. So in the course of six years the
• 1:11:46
  Speaker 4: control group non peptide, eighty two percent of those people died.
• 1:11:50
  Speaker 4: Eighty one point eight Okay, normal for that part of
• 1:11:53
  Speaker 4: the world. This is the Ukraine in Russia, normally for
• 1:11:56
  Speaker 4: the age bracket. Now go to the next call them
• 1:11:59
  Speaker 4: over pinyal glenn peptide. That group, just using the pineal
• 1:12:03
  Speaker 4: peptide cut the mortality rate down to forty six percent
• 1:12:07
  Speaker 4: forty five point eight percent, from eighty two percent to
• 1:12:11
  Speaker 4: basically forty six percent. Then he added a second peptide,
• 1:12:15
  Speaker 4: a thymus peptide, to another group where they were taking
• 1:12:18
  Speaker 4: both the pineal and the thymus, and it dropped the
• 1:12:21
  Speaker 4: mortality rate to thirty three percent from a pent So in.
• 1:12:27
  Speaker 1: This study, they didn't use the epitolon.
• 1:12:29
  Speaker 2: They're just using the two most popular of the bioregulators
• 1:12:34
  Speaker 2: that you and I have talked about before is the
• 1:12:36
  Speaker 2: thymus and the pineal and they okay, all right, well,
• 1:12:41
  Speaker 2: I wonder what would have happened if they had the
• 1:12:43
  Speaker 2: pitolan in there as well, given the you know, the
• 1:12:48
  Speaker 2: staggering statistics about the use of a pitolon.
• 1:12:53
  Speaker 4: Yeah, but they're comparable. They're they're both pineal glenn targeted.
• 1:13:00
  Speaker 3: Yeah.
• 1:13:01
  Speaker 4: The message here is using just two peptides, and these
• 1:13:06
  Speaker 4: are the foundational peptides in our program, using just these
• 1:13:09
  Speaker 4: two peptides. And again this is a six year study,
• 1:13:13
  Speaker 4: but these people only use the peptides for.
• 1:13:15
  Speaker 3: The first two years.
• 1:13:17
  Speaker 2: I know.
• 1:13:17
  Speaker 4: That's amazing that you went from eighty two percent to
• 1:13:20
  Speaker 4: thirty three percent with two peptides. Now, the interesting thing
• 1:13:23
  Speaker 4: is today we have twenty one of these peptides, not
• 1:13:28
  Speaker 4: just two. We have peptides for every major organ I'll
• 1:13:31
  Speaker 4: show you list it in a moment.
• 1:13:33
  Speaker 2: Says twenty two natural peptide bioregulator extracts manufactured in Norway.
• 1:13:39
  Speaker 3: Yeah, there's one of them.
• 1:13:41
  Speaker 4: That's kind of quasied, so sometimes we'll say there's twenty
• 1:13:44
  Speaker 4: one and sometimes twenty two. Okay, okay, So these in fact,
• 1:13:48
  Speaker 4: these are the peptides at this point natural extracts from Norway.
• 1:13:54
  Speaker 4: So there's brain, heart, bladder, pineal, glen, adrenaline, glenn, also prostate, kidney,
• 1:14:01
  Speaker 4: stomach testing, thyroid, in other it's basically the major organs.
• 1:14:06
  Speaker 3: There is a peptide that is available. Now.
• 1:14:11
  Speaker 4: The question is that people get confused. There's a difference
• 1:14:14
  Speaker 4: between bioregulators and the synthetic peptides that are very, very
• 1:14:18
  Speaker 4: popular these days. The bioregulators are targeting organs to do
• 1:14:25
  Speaker 4: regeneration and their natural extracts okay, and they have long lasting,
• 1:14:29
  Speaker 4: permanent results, but it takes a couple of years before
• 1:14:33
  Speaker 4: you start to see any results at all. Probably the
• 1:14:37
  Speaker 4: thyroid is the one that we see maybe in eight
• 1:14:40
  Speaker 4: or nine months looking at lab results before and after
• 1:14:42
  Speaker 4: that we start to see the needle moving. But most
• 1:14:45
  Speaker 4: of these peptides require a minimum of year. We can
• 1:14:49
  Speaker 4: typically with the pineal gland peptides, we can move the
• 1:14:52
  Speaker 4: telomere markers by a significant amount in the first year,
• 1:14:58
  Speaker 4: a lot more in the second year, but the other organs,
• 1:15:01
  Speaker 4: because what we're doing is regenerating an organ. I mean,
• 1:15:04
  Speaker 4: think about that, we're regenerating a heart, a brain, and
• 1:15:07
  Speaker 4: so forth. Those take three to four years. We start
• 1:15:10
  Speaker 4: to see improved usually about year two on those other organs.
• 1:15:15
  Speaker 4: On the other hand, since you know a lot about
• 1:15:17
  Speaker 4: the synthetics, their lab synthesize, they're very quick and they
• 1:15:21
  Speaker 4: have short term results, and so we're talking about things
• 1:15:24
  Speaker 4: like BPC one fifty seven, TV five hundred and so forth,
• 1:15:28
  Speaker 4: and of course the whole new gpl ones that are
• 1:15:31
  Speaker 4: just wonderful kinds of things. What people are not understanding
• 1:15:35
  Speaker 4: is that some of them, like retatruetide, the most recent one,
• 1:15:41
  Speaker 4: not only they think of it as a weight loss
• 1:15:44
  Speaker 4: intervention it is that, but the clinical studies they are
• 1:15:47
  Speaker 4: showing significant and benefits to other organs like, for instance,
• 1:15:53
  Speaker 4: kidneys and liver. Okay, visual fat is disappearing at the
• 1:16:00
  Speaker 4: same time that the other fat is disappearing.
• 1:16:03
  Speaker 3: So these are used together as far as.
• 1:16:07
  Speaker 4: I'm concerned, and we're kind of getting to that point
• 1:16:10
  Speaker 4: where people are realizing that they're both helpful. I use
• 1:16:14
  Speaker 4: a number of these synthetic peptides myself, and so Marroring
• 1:16:19
  Speaker 4: the bioregulators for long term with the synthetics for short
• 1:16:23
  Speaker 4: term is a wonderful, wonderful protocol.
• 1:16:27
  Speaker 2: Well, I'm so glad I asked that question in the beginning,
• 1:16:29
  Speaker 2: because that is probably the sixty four thousand dollars question
• 1:16:32
  Speaker 2: people keep repeating because they don't know, and most people
• 1:16:38
  Speaker 2: do not know about peptide bioregulators, but they do know
• 1:16:41
  Speaker 2: about the.
• 1:16:43
  Speaker 1: Synthetics.
• 1:16:44
  Speaker 2: So the fact that you've just explained and people now
• 1:16:48
  Speaker 2: can understand if they want the longer term effects of
• 1:16:53
  Speaker 2: improvements and the organ regeneration, it's the peptide bioregulators, but
• 1:16:59
  Speaker 2: they are synered with the synthetics.
• 1:17:02
  Speaker 1: Yes, Okay, Bill, we are running out of time.
• 1:17:06
  Speaker 2: I think Tony has been very generous and letting us
• 1:17:09
  Speaker 2: stay over, and so I'm thinking that maybe we need
• 1:17:13
  Speaker 2: to I hate to do this to you, but I'm
• 1:17:15
  Speaker 2: thinking that we may need to wrap up. Is there
• 1:17:19
  Speaker 2: any way that you can summarize these last ones in
• 1:17:22
  Speaker 2: a couple of minutes, Let's.
• 1:17:23
  Speaker 3: See where we were going to go. This is.
• 1:17:25
  Speaker 4: Let me talk about this and then we'll wrap it up.
• 1:17:28
  Speaker 4: We talk about organ regeneration. What this slide shows is
• 1:17:32
  Speaker 4: that before and after with respect to vision.
• 1:17:38
  Speaker 2: And by the way, Bill, that's where David Sinclair got
• 1:17:41
  Speaker 2: the most amazing funding.
• 1:17:44
  Speaker 1: They're working on.
• 1:17:45
  Speaker 2: The glaucoma, which is so so this is very appropriate
• 1:17:48
  Speaker 2: that you brought the slide.
• 1:17:50
  Speaker 1: Added the slide.
• 1:17:51
  Speaker 4: Russians have been doing this. I mean where you see
• 1:17:55
  Speaker 4: the yellow and the black and the reds or that
• 1:17:57
  Speaker 4: means impaired vision. Greens means that you have some vision.
• 1:18:00
  Speaker 4: So when you look at this first one, the diabetic retropathy,
• 1:18:04
  Speaker 4: the patient came in with what you see on the left,
• 1:18:07
  Speaker 4: all the red and the yellow. Two years later they're
• 1:18:09
  Speaker 4: green in the case that they're back to pretty normal vision.
• 1:18:13
  Speaker 4: Same is true with macular degeneration. Same is true red
• 1:18:16
  Speaker 4: and I is pickmintosa. They've been doing this day in
• 1:18:19
  Speaker 4: and day out for twenty years. They have a special
• 1:18:21
  Speaker 4: lab just for a vision. So let's end this right there.
• 1:18:25
  Speaker 4: I think now we're getting into the biological age reversal.
• 1:18:29
  Speaker 4: We can maybe pick this up at a later time.
• 1:18:31
  Speaker 1: I think that's a great idea.
• 1:18:33
  Speaker 2: And you know, I just wanted to have a moment
• 1:18:35
  Speaker 2: to tell people about your clinical trials and that there
• 1:18:38
  Speaker 2: is a possibility if anyone is interested. And I know
• 1:18:42
  Speaker 2: from our last time three years ago, we had so
• 1:18:46
  Speaker 2: many people contact me about they be being in your
• 1:18:51
  Speaker 2: clinical trials, So could you just give us like a
• 1:18:54
  Speaker 2: quick explosa on that and how, and then I'll tell
• 1:18:57
  Speaker 2: them how they can get involved connect with you.
• 1:19:01
  Speaker 3: Sure, we have I don't.
• 1:19:03
  Speaker 4: Know, one hundred and fifty plus or minus people primarily
• 1:19:06
  Speaker 4: physicians and healthcare people, but some you know who are
• 1:19:10
  Speaker 4: not that. People are just passionate about their health in
• 1:19:13
  Speaker 4: our study. And we ask people to stay in the
• 1:19:19
  Speaker 4: study voluntarily for three to four years because it takes
• 1:19:22
  Speaker 4: that long to get to those criteria that I showed
• 1:19:26
  Speaker 4: you earlier. And it involves it's not very difficult, involves
• 1:19:31
  Speaker 4: taking probably two capsules a day for maybe four or
• 1:19:36
  Speaker 4: five different peptides you know, say the kid need deliver
• 1:19:39
  Speaker 4: the brain, but only typically only ten days out of
• 1:19:43
  Speaker 4: the month, and then you're off everything for twenty unlike
• 1:19:45
  Speaker 4: pharmaceuticals where you're on them for life. It's a very
• 1:19:49
  Speaker 4: different kind of approach. And what we do is we
• 1:19:52
  Speaker 4: do some initial lab testing for telomeres and epigenetics and
• 1:19:57
  Speaker 4: we get those numbers in terms of they will show
• 1:20:00
  Speaker 4: us your biological age based on telomeres and epigenetics and
• 1:20:04
  Speaker 4: we then look at any.
• 1:20:06
  Speaker 3: Other health issues.
• 1:20:07
  Speaker 4: I'm not a doctor, so I can't treat those, but
• 1:20:09
  Speaker 4: I can sort of. I can't ignore them. So when
• 1:20:12
  Speaker 4: we have a person coming in who has a health issue,
• 1:20:15
  Speaker 4: we create a protocol to deal with the lab results,
• 1:20:19
  Speaker 4: the biological age results, the pace of aging, and then
• 1:20:23
  Speaker 4: any health issues, and we then build them a protocol
• 1:20:26
  Speaker 4: that's unique to them for the next twelve months of
• 1:20:29
  Speaker 4: the peptides that would be appropriate. Typically it's about three
• 1:20:33
  Speaker 4: to five different peptides a month, so we rotate multiple
• 1:20:37
  Speaker 4: times during that twelve months, and then at the end
• 1:20:40
  Speaker 4: of three or four years.
• 1:20:41
  Speaker 3: Pretty much everybody gets to their goals.
• 1:20:43
  Speaker 4: Naively, Cavinson and I thought that it would only last
• 1:20:46
  Speaker 4: three to four years. The problem is when people get
• 1:20:49
  Speaker 4: to the third and fourth year and we've hit the goals,
• 1:20:51
  Speaker 4: they don't want to leave. So we've yeah, we developed
• 1:20:55
  Speaker 4: a little maintenance program. Anyway, that's the background.
• 1:20:58
  Speaker 2: And because you're so busy, we really do not want
• 1:21:03
  Speaker 2: We really encourage people to contact me first and then
• 1:21:06
  Speaker 2: I will make all the arrangements for connecting with you.
• 1:21:11
  Speaker 2: But my just so people know my phone number, the
• 1:21:14
  Speaker 2: best way to reach me is by text or sell call,
• 1:21:18
  Speaker 2: and that's area code eight oh eight six three.
• 1:21:21
  Speaker 1: Nine zero nine zero four.
• 1:21:24
  Speaker 2: And while it's an eight oh eight area code, I
• 1:21:27
  Speaker 2: spent many years developing real estate and Hawaii and I
• 1:21:30
  Speaker 2: never gave up that number. But I do live in
• 1:21:33
  Speaker 2: the Bay Area, so it's a specific time zone. If
• 1:21:37
  Speaker 2: you're going to call me, uh so, Bill, I'm gonna
• 1:21:40
  Speaker 2: say goodbye because I.
• 1:21:41
  Speaker 1: Don't want to.
• 1:21:42
  Speaker 2: I don't wanna, you know, overreach with with my wonderful producer.
• 1:21:48
  Speaker 2: But we have had so much information today. I hope
• 1:21:52
  Speaker 2: people are taking have taken notes when they when they
• 1:21:56
  Speaker 2: watch this, or will take notes when they watch this,
• 1:21:59
  Speaker 2: I should say.
• 1:22:00
  Speaker 1: And we will schedule again.
• 1:22:03
  Speaker 2: And so let's just say we stopped at peptide bioregulator's
• 1:22:07
  Speaker 2: biological age reversal.
• 1:22:09
  Speaker 1: And what do we need, like another hour to do.
• 1:22:12
  Speaker 4: The rest or No, I'd say forty minutes minutes, okay, Well.
• 1:22:17
  Speaker 2: Then we usually allocate fifty minutes and then the other
• 1:22:20
  Speaker 2: ten minutes. I'll ask you some more questions.
• 1:22:23
  Speaker 1: If that's okay, that's great.
• 1:22:24
  Speaker 4: One last thing I want to say, I purposely am
• 1:22:27
  Speaker 4: difficult to contact directly.
• 1:22:29
  Speaker 3: I never give up more information.
• 1:22:32
  Speaker 1: I know all that stuff.
• 1:22:33
  Speaker 3: So you must go through Michelle. Why she will not
• 1:22:37
  Speaker 3: reach me.
• 1:22:37
  Speaker 4: She's going to be the person that sort of does
• 1:22:40
  Speaker 4: a little screening to make sure that you understand the program,
• 1:22:43
  Speaker 4: and then she then contacts me.
• 1:22:45
  Speaker 2: And I do want people to know that this is
• 1:22:47
  Speaker 2: not one of those complementary scientific studies out of the
• 1:22:51
  Speaker 2: government that this is. You know, Bill's time is extraordinarily valuable,
• 1:22:56
  Speaker 2: and this is an expensive study to be in the
• 1:23:00
  Speaker 2: clinical trials. So I'll talk about that with anyone that's interested.
• 1:23:03
  Speaker 2: And there is a difference between a medical professional and
• 1:23:07
  Speaker 2: a general consumer in terms of the pricing, So we'll
• 1:23:12
  Speaker 2: go over there if you're if you are interested, then
• 1:23:15
  Speaker 2: you know, just please feel free to call me. Okay, Bill,
• 1:23:18
  Speaker 2: thank you so much for being our guest today again,
• 1:23:21
  Speaker 2: and now we know we're going to have a round three.
• 1:23:24
  Speaker 2: I just have to find a time for you, because,
• 1:23:26
  Speaker 2: like you, we're booked until twenty twenty seven.
• 1:23:29
  Speaker 1: Right now, so that's a good news for us.
• 1:23:31
  Speaker 2: But I'm just so and so grateful to you and
• 1:23:36
  Speaker 2: all that you're doing for people and their well being.
• 1:23:40
  Speaker 2: So you take care and have a wonderful, wonderful weekend.